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DEDICATION
This thesis marks the culmination of a medical career which has been
considerably shaped by contact with three men. My early interest in drug action and
evaluation was stimulated by Dr. Garnett Davey, the discoverer of the dihydrofolate
antagonist proguanil (Paludrine), still one of the safest and most widely used drugs for
malarial prophylaxis and treatment. In the early 1950s Dr. Davey used to stay with us
in East Africa while he conducted clinical evaluations of the anti-malarial properties of
the drug. Some years later, when he was the Director of Research for the I.C.I.
Pharmaceuticals Division, Dr. Davey encouraged me as I contemplated a career in the
pharmaceutical industry and during my time as a house surgeon, invited me to spend
four days as his guest at Alderley Park, the I.C.I Research Centre. This was highly
instructive and opened my eyes to the opportunities and activities of physicians in the
pharmaceutical industry, particularly when I was able to spend time with scientists of
the calibre of Dr. James Raventos who discovered the general anaesthetic properties of
halothane, and a young physician who was using remote, single channel ECG
telemetry in dogs to study a new class of drugs that slowed the heart rate and lowered
blood pressure. He later became Sir James Black and the drugs, of course, were the
(3-adrenergic blockers.
There is a little known aside to the p-blocker story: after the concept of a- and
p-adrenergic receptors had been proposed in 1948 by Alquist, the first p-blocking drug
was synthesised not at I.C.I, but at Eli Lilly in Indianapolis, by Irving Slater, Ph.D.
His compound was a dichloro analog of isoproterenol which, unfortunately, was not
clinically useful because it also possessed potent sympathomimetic properties. His
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data were published in 1958 and he kept a sample of the compound on a shelf in his
office until he retired. In their 1962 paper describing the first clinically useful |3-
blocker, 'Alderlin', Black and Stephenson acknowledged the precedence of Slater and
his colleague Powell. In those days I.C.I, were attempting to establish 'name
recognition' for these new compounds, so the next two (3-blockers were named Eraldin
and Inderal, all semi anagrams and a play on the word Alderley.
While a medical student at Edinburgh in the second half of the 1950s I had the
immense good fortune to be taught therapeutics and materia medica by Professor
(later Sir) Derrick Dunlop. His teaching was memorable for its style, quips and bon
mots with which he peppered his presentations, and for the common sense that he
attempted to instill into our practice. Following the thalidomide disaster he left
Edinburgh at the Government request to create the Dunlop Committee, the drug
watchdog committee as the British press dubbed it. As a house physician in Ward 28,
I had prescribed thalidomide to elderly in-patients as a sedative, until my Chief, Sir
James Cameron, who was President of the Royal College of Physicians of Edinburgh at
the time, pointed out the reports of neuropathy that had been associated with the
drug, so the creation of this eponymous committee to regulate the evaluation and
marketing of new drugs was intriguing. Later still, when Sir Derrick had become
'Gamekeeper turned poacher,' as he put it on joining Sterling-Winthrop as a corporate
Director, I, as Medical Research Director for Winthrop in Europe, came to know him
from a different perspective as we discussed new drug evaluation and the regulations
surrounding these activities.
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During my training in Edinburgh I realised that with anaesthesia I was practicing
applied clinical pharmacology, at that time a fledgling and barely recognised speciality.
Anaesthetists have an advantage over physicians (Americans call them 'internists') in
that we give our drugs and watch them take effect, whereas physicians prescribe
drugs but very seldom see the patient actually take them or see the immediate or
delayed effects.
By this stage in my training I had developed considerable interest in the subject
of pain and its relief, so I joined Sterling-Winthrop to learn more about drug discovery
and drug evaluation in general, but more particularly to work with their newly
synthesised analgesic pentazocine, (Fortral in the UK, Talwin in the US). As a result,
at the 1966 Annual Meeting of the Scandinavian Society of Anaesthetists in
Copenhagen I first met Dr. Henry Beecher, Dorr Professor of Anesthesia at Harvard
University, and at that time the doyen of analgesia and analgesic research world wide.
In addition to articles describing his observations on the effect of pain in United States
soldiers wounded during the Anzio beachhead landings of World War Two Beecher had
published, in 1955, one of the most widely quoted papers on placebo (which,
incidentally, he pronounced piayseebo) and a book on the measurement of subjective
responses, of which pain is perhaps the most subjective of all. He had also written
articles and a book (my copy has a generous inscription from him) critical of many
practices in the United States which had been performed under the banner of medical
research. As I came to know Beecher we had many discussions about clinical
research, drug evaluation, subject protection and subject abuse and, no surprise, the
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role and place of placebo in medical research. Many of the study designs which I have
employed for the evaluation of analgesics and other drugs grew from these discussions.
With this background perhaps it is hardly surprising that I developed an interest
in all aspects of drug development, and I date my interest in the use of placebo from
my meeting Beecher. I believe that, at some time or another, I have read everything
that he published on the subject and I hold him in high esteem, quoting from him
frequently and extensively.
To these three senior colleagues, who at different times and in different ways,
befriended, stimulated the interest of and encouraged a very junior colleague, I owe
an enormous debt. As I come to the end of my own career I hope to make a
compelling argument for the retention of placebo as a research tool for the evaluation
of new drugs. If this goal is achieved then credit is due to these three men, to whom
I dedicate this thesis as a belated token of thanks for their guidance, encouragement,
willingness to teach and share ideas.
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AN EXPLANATION
I recognise this thesis is somewhat unusual in that it does not follow the
conventional pattern of describing and presenting results and interpretation of direct
experiments in the basic sciences or clinical medicine. It does, however, examine
and discuss a subject that is critical to almost all direct clinical evaluation and
assessment.
Advances in medicine depend upon the results of clinical investigations. If
these investigations are not well conceived or designed, if they lack scientific rigor or
assay sensitivity, then the ethics of conducting the investigation can be questioned. If
the results are flawed or do not lend themselves to valid interpretation then they
become misleading, at best, possibly dangerous and probably useless. Fortunately,
there is available an agent which can help to avoid many of these problems:
unfortunately, this agent and its effects are misunderstood and misinterpreted by




Throughout this thesis my primary hypothesis is that the use of placebo
is essential for most clinical investigations in modern medical research.




My secondary hypotheses concern:
i). the misunderstanding of what placebo was and has now become;
ii). how the concept of placebo entered the medical lexicon and how
its use in medical practice was heavily influenced by the
dictionary definitions;
iii). how physicians in the 19th. and early 20th. century used placebos
in their practice and understood how the placebo effects could be
used to benefit their patients;
iv). how the modern therapeutic revolution has created effective
drugs so that use of the placebo as a treatment is no longer
necessary or acceptable;
v). how modern medical practice, although rightly abhorring placebo
as treatment, fails to understand and appreciate the ever present
ubiquity of the placebo effects;
vi). how this has created confusion so that critics attribute to placebo
problems which should more accurately be aimed at other targets
such as the informed consent process;
vii). how use of placebo is not synonymous with xno treatment' and
how imaginative study design permits all patients in the study to
receive standard medical care even with the inclusion of a
placebo; and
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viii). how omitting placebo may invalidate the study by reducing assay
sensitivity so that Type I and Type II errors are undetected,
leading to erroneous interpretation of the results.
It is true that my thesis is not concerned with a single study, but instead
I have reviewed and described a range of studies, covering several different
therapeutic areas, including many studies that I either designed or with which I
was closely involved, to support my contention that the critics are wrong and
that placebo is an essential tool in many aspects of modern medical research.
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INTRODUCTION.
"When I use a word," Humpty Dumpty said, in a rather scornful tone, "it means just
what I choose it to mean - neither more nor less."
"The question is," said Alice, "whether you can make words mean so many different
things."
"The question is," said Humpty Dumpty, "which is to be master - that's all."
Through the Looking Glass.
Lewis Carroll, 1832 -1898.
Controversy, argument and criticism are strangers neither to medical
practitioners nor to the practice of medicine. The great advances in medicine since the
end of the Second World War have generated new ethical arguments and divisive
controversies far beyond anything conceived in that first code of ethics for physicians,
produced approximately 2,500 years ago in the form of the Hippocratic Oath. These
impressive changes have demanded reconsideration of, for example, the ethics of
access to patient records, rationing of medical care, resuscitation of patients,
continuing treatment of comatose patients, genetic manipulation and
pharmacogenomics, to name only a few topics of current discussion. The role of
'alternative' medicine, the treatment of members of religious sects who refuse blood
transfusion, and the availability of organ transplantation have expanded the religious,
ethical and moral aspects of medical treatment with consequent impact on the
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responsibilities of the physician. Finally, resulting directly from the Nazi atrocities
committed on prisoners during the Second World War, there has been increased
scrutiny of all aspects of patient protection when they are subjects in clinical trials and
experiments.
In this maelstrom of discussion there remains Placebo, which is the first person
singular, future indicative of the Latin placere, meaning "I shall please." Just how this
word came to evolve into one of the most divisive enigmas of modern medicine is an
interesting tale.
Parts I - IV of the thesis provide an historical review of the transmogrification
of the word and conclude with a review of the medical use of placebo from the 19th.
and 20th. century. Part I starts with the early translations of the Bible and explains
the background that led to the confusion and criticism. Part II describes how the
meaning of the word changed from Biblical days through its appearance as a noun in
the Middle Ages, with examples from the works of Chaucer. Part III is concerned with
the appearance of definitions in medical dictionaries towards the end of the 18th.
century, and considers the changing definitions through the 19th century, up to
present day dictionaries.
While there is no doubt that placebos were used extensively for treatment
during the 19th. and early 20th. centuries there is a marked paucity of publications
describing this use, but even in these days there were obvious differences of opinion
among members of the profession as to the ethics of this use and whether physicians
who prescribed placebos were not being inherently dishonest with their patients. In
the aftermath of the Second World War, placebos were still being used as treatment,
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but now practitioners were more willing to discuss openly their practice, some
defending the placebo as a useful therapeutic tool.
Part V considers what the placebo is and what the components of the placebo
effect, or response, may be. Understanding of the concepts and use of placebo has
not kept pace with the monumental advances in the science of modern medicine in the
last half century, and physicians tend to treat the concept of placebo with disdain or
disparagement. Their own role as a component of the placebo effect and their ability
to induce huge variability in the placebo response or how this can be affected by the
interactions of patient and physician, seem not to be appreciated.
These effects are discussed in Part VI, and although there may be no role for
the placebo in modern medical practice the placebo effect pervades every kind of
patient-physician relationship. These same components impact every clinical research
project at least as much as they impact daily clinical practice, probably more so.
Criticism of the use of placebo in clinical research is not lacking and Part VII
presents each criticism or facet of the criticism, discusses its rationale and the factors
that provoked it. I then attempt to answer each criticism, to disprove the validity or
at least to offer an alternative explanation or interpretation.
The important role of placebo in medical research is addressed in Part VIII and
subsequently. Placebo can make contributions that are directly applicable to medical
practice, solving problems and providing answers to patient queries. Examples are
presented, emphasing the blurred line that separates medical practice from medical
research. Part IX describes the different phases of a clinical development programme
for a new drug, briefly looks at study designs and finds roles for placebo in different
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designs. However, it is the use of placebo as a comparator in clinical trials that draws
the ire of the critics and in Part X examples are offered from Phase I and II studies in
which I had substantial involvement in the planning, monitoring, conducting and even
as a participating subject, to show the different functions of the placebo as well as
recognising that it is not always necessary to have placebo as a study component.
The expanded studies of Phase III and IV create different problems which are
identified and discussed in Part XI, and the distinction between placebo effect and the
perceived placebo effect is introduced. Part XII examines specific studies, including
several of my own, to explain the use of placebo in providing assay sensitivity.
Because a full reference is provided for each study I have not repeated all the study
details but have concentrated on that aspect which illustrates the point to be made and
suggested some study designs that can be used to limit exposure to placebo.
Regarded as ineffective and putting patients at risk, placebo is usually seen as a villain,
but the truth is somewhat different, and in Part XIII I suggest that placebo actually
reduces the number of patients exposed to risk in studies.
Throughout the thesis each Part builds on the previous Parts, so there is
constant cross referring, in the form of a musical Rondo, but finally, in Parts XIV and
XV the arguments against placebo are challenged once more, leading to the
conclusion that exclusion of placebo would invalidate much of the data obtained from
clinical trials while wasting resources and putting at risk patients for no benefit to
themselves or society in general. In short, I submit that placebo, when used in
studies with full, informed consent of the participants, is an essential and integral
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component to provide the assay sensitivity without which many studies would not be
ethical.
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THE TRANSMOGRIFICATION OF PLACEBO
Confusion and controversy
I. THE BIBLICAL ORIGINS
a) 'In the beginning was the word.'
Borrowing the opening line from the Gospel according to St. John seems
appropriate because Placebo first appeared in a Biblical translation of Psalm 114. In
later translations the word was moved to Psalm 116 and modern interpretation has it
that the original translation may have been incorrect. However, to appreciate the
problems faced by translators of the original texts and explain how the various changes
in location and meaning came about it is necessary to embark on a short Ecclesiastical
journey.
The Greek language Septuagint version of the Bible, so named for the
72 linguists who were sent to Alexandria by Ptolemy II Philadelphus (285 - 246 BC) to
translate the Hebrew Biblical texts, is the earliest extant translation of the Bible (1).
The translators encountered great difficulties with the original Hebrew language as they
had incomplete texts from which to work and no knowledge of the Hebrew technical
terminology which had become obsolete over time (2). Additionally, in ancient times
there was no fixed or uniform system of chapter divisions and often there was no
indication of transition from one psalm to another, so varieties of verse groupings were
possible. For example, in the Hallelujah Psalms, numbers 111 - 117, the Septuagint
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translators combined 114 with 115 and divided 116 into two. By the 3rd. century, as a
result of accidental corruptions and errors by scribes and copyists, versions of the
Septuagint text varied from copy to copy. Although Latin translations of the
Septuagint had existed from the 2nd. century textual confusion in these Old Latin
versions had made them unacceptable to the Church (3). This situation had to be
remedied, so towards the end of the 4th. century Pope Damasus commissioned his
secretary, Eusebius Hieronymous (c. 347 - 420, later to become St. Jerome), to
produce a new, acceptable, Latin translation of the Bible.
b) The translations of Saint Jerome.
St. Jerome was extremely well qualified for this commission. Born in Stridon in
Dalmatia, he was the outstanding scholar of his age, remembered for his erudition
and understanding of the Bible. Regarded as the most learned of the Latin fathers of
his day, fluent in Latin and Greek, he learned Hebrew so effectively that he was able
to give lessons on the Hebrew text of the Psalms.
St. Jerome started with a translation of the Psalms and the Book of Job and
eventually produced three distinct Latin translations of the Psalms, all still extant (4).
His first was a translation into Latin from the Greek Septuagint version. Although not
totally accepted, this translation was incorporated into the liturgy by the Catholic
Church at Rome and is known also as the Roman Psalter. The second translation,
again into Latin from the Greek, and published in Palestine, was based on the
Hexaplaric Septuagint. This version, popular in Gaul, became known as the Gallican
Psalter, and was adopted into the third translation. St. Jerome found the same
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difficulties with translating the Psalms as were found by his predecessors, and
although he brought the Latin closer to the Hebrew, the Gallican version still differs
from the Hebrew version in many places. For example, in the Gallican version Psalm
14 includes the addition of three verses from St. Paul's Epistle to the Romans, which
obviously could not have been in the original Hebrew text.
After these two attempts St. Jerome realised the futility of continuing to
translate into Latin from the Greek text. Between the years 391 - 406, making a
fresh translation directly from the Hebrew, he produced a Latin version of the Old
Testament which is known as the editio Vulgate, or common version (5). Initially this
was received with suspicion because it diverged significantly from the Old Latin version
and seemed not to be in accord with the then traditional versions. By the 8th. century
however, the superiority of the third translation led to its ultimate acceptance. With
the passage of time and continuing copyist errors the Old Latin and Vulgate versions
tended to become composite, as might be expected with a new revision of an existing
text, although scribal corruptions and variations have been found (5) in the more than
8,000 surviving manuscripts.
c) The Introduction of Placebo.
The first appearance of placebo is in Psalm 114, verse 9, of the Gallican
version, based on the Greek Septuagint (6). This translation divides the Psalms in a
different manner from the other Bibles and it has been noted that, in addition to the
translation difficulties already described, the Psalms created additional problems for a
translator because the Psalter was not only a book to be read, but also a song to be
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sung (6). The first line of the verse appears as Placebo Domino in regione vivorum
and this has been translated into English as "I shall please the Lord in the land of the
living." Confusion has occurred because in other translations, in particular the
Vulgate, this verse has been moved to Psalm 116 verse 9, with Psalm 114 reduced to
8 verses. It has been suggested (7) that this change occurred because the original
Hebrew line et'haiekh iiphnay adonai b'artzot hakhayim (translated as "I will walk in
Yahweh's presence in the land of the living") was attracted to Psalm 116: verse 8
under the influence of the parallel Psalm 56, where verse 13 is very similar to verses 8
and 9 in Psalm 116 (Tor you have rescued me from death to walk in the presence of
God in the light of the living").
Controversy has arisen also because of St. Jerome's use of placebo ("I shall
please") for the Hebrew word et'haiekh ("to walk"). This anomaly has been
reported by several authors (8, 9, 10) and defended or explained by others. The
Latin has been accepted as an accurate, direct translation from the original Greek in
the Septuagint, EvapsaT-qaa) svco mov Kvpiov sv ycopa t^covrcov and also as a
meaningful interpretation of the Hebrew (6). Jacobs suggests that while the simple
Hebrew elech means "I will walk", the reflexive grammatical form et'halech has a
more purposeful meaning in keeping with "I will be in step with" or "I will please."
He further notes that this use of "walking" is translated several times in the
Septuagint version of Genesis as "pleasing" (6). Support is provided by Pepper (10)
who notes that the Hebrew can be translated as "to walk habitually" and this is used
in phrases such as "he walked before God" and therefore by implication, was pleasing
God. However, an alternative translation of the Greek (11) proposes "I will be
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pleased in the company of the Lord in the land of the living." Another explanation as
to why St. Jerome should have chosen placebo for his Latin translation is that he may
have believed that anyone who walked before the Lord would please Him and perhaps
used the word for euphony or metre (9).
In the 15th. century the development of printing made possible the production
of consistent and stable texts without corruption of scribal errors from copy to copy.
Taking advantage of these benefits, a new version of the Vulgate was produced in
1592, under the auspices of Pope Clement VIII. In 1611 the King James VI version in
English, the first translation under Royal patronage since the Septuagint, was
published. Forty seven scholars participated in this effort which understandably shows
a lack of consistency, but it is generally accepted that the Jewish sources involved in
the translation helped to produce a version that is the most faithful to the original
Biblical language (5). In the King James' version, Psalm 116 verse 9 is translated as
"I will walk before the Lord in the land of the living." and this is consistent with Psalm
56 verse 13. It would seem that this time the scholars did not agree with or accept St.
Jerome's interpretation.
It is worth noting that even with the advantages of printing these 'modern'
translations, versions were still published which contained differences or errors. For
example, in 1611, the Book of Ruth 3: verse 15, contained the "He" and "She"
versions. In 1631, publication of the 'wicked' Bible in which the word NOT was
omitted from the seventh Commandment (Exodus 20: verse 14) cost each of the
printers a penalty of £300 and in 1717 the 'vinegar' Bible resulted from a copyist error
in the heading for Chapter 20 of the Gospel according to St. Luke.
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The discovery of new documents such as the Dead Sea Scrolls has expanded
and changed interpretations of the Hebrew, Greek and Latin words so it is hardly
surprising that St. Jerome's interpretation of placebo has been challenged, deemed
incorrect, altered and generally surrounded with controversy.
d) Was the best word chosen?
Reviewing the proposals, suggestions and difficulties described above, I prefer
to believe that St. Jerome, with his detailed and extensive knowledge of Latin and
Greek, deliberately chose Placebo to convey the impact, nuance and shade of
meaning that he wanted to impart. With his linguistic skills he surely would have used
ambulato ("I will walk") if indeed he thought that was what the Psalmist intended.
Words change their meaning, emphasis and implication over time and similar subtle
changes occur frequently even in the same language, as we see today between
modern British English and American English (12). To take a few examples starting
with one from medicine, the term Sister in Britain is used properly and respectfully to
address the senior member of the nursing staff. Such an appellation in the United
States, however, is likely to be greeted by the recipient with much less enthusiasm!
In Britain the word stupid is regarded as a very mild rebuke, encompassing a hint of
the bizarre, but in the United States it is regarded with much more gravitas and with
strong overtones of insult. Instead, Americans use dumb for the mild rebuke.
Perhaps the biggest change in recent years has seen the word gay pass from
being a lightheaded, happy adverb or adjective to a noun that describes a particular
life style. Other words may change their meaning less dramatically, for example the
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implication of presently changes from the British procrastination of some time in the
near future to the American imperative, right now. Momentarily changes from the
British starting and then abruptly stopping to the American interpretation of starting in
a moment.
So, how will a translator in the future be expected to know these subtle
differences and nuances and would it be considered incorrect if one translation refers to
a female sibling of a member of staff, the second to a person who is mute, the third
to express an emotion and the fourth....?
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II. IN THE MIDDLE AGES
a) Changing the verb to a noun
Sometime in the 13th. century the word placebo entered the English language,
variously translated as 'to please', 'to give pleasure', 'to be approved', 'to be pleasing',
'to be agreeable', 'to suit', 'to satisfy', (13). Acceptance of St. Jerome's translation
Placebo Domino in regione vivorum by the Roman Church led to the incorporation and
first use of the word into the first antiphon of Vespers for the Dead. In the 13th. and
14th. centuries these Vespers, or Lauds, were recited and sung after the Mass at the
graveside (13). In time this service came to be known by the first word, and family
members and mourners attending the Burial Mass would sing the Placebo (9).
Towards the end of his life, John Wyclif (1330 -1384), theologian, church reformer
and promoter of the first complete translation of the Bible into English, perceived a
change in Ecclesiastical outlook when he wrote ' Prelatis ben more bounden to this
prechynge than to sei matyns, masse, evensong or placebo.' This quotation is
only one example of several similar quotes from religious leaders and writers, including
John Knox, provided by the New English Dictionary (14).
At funerals Priests and Friars would pester the populace for money to sing these
prayers, often joined by professional mourners who attended the interment and also
sang Placebos at the bier, sometimes in lieu of the family and always in the hope of
being remunerated by the grateful family members (13, 15). For those Friars known
as Limiters this was an important source of income because, as the name suggests,
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they were granted by the town and city fathers the right to beg for aims only in certain
limited districts of the town or city. Figure 1 shows a memento moriof the Placebo in
the Middle Ages (16). A corpse has been buried in a grave. The mourners in black,
with a child present, are probably the family members while the two men beside the
Priest may be Friars or professional mourners. The text, clearly headed Placebo,
exhorts the Christian man to contemplate death steadfastly and remember his own
impending end.
By the 14th. century the word placebo had taken on a secular meaning,
becoming derisive and meaning To sing, be servile, time-serving or to play the
sycophant' (15). In the Parson's Tale, Chaucer writes Tlatereres been the dueles
Chapellyns that syngen eure Placebo' and in a modern translation, 'Flatterers are the
Devil's Chaplains, always singing Placebo.' (9). It is not difficult to understand this
transition, given the role of the Priests, Friars and other mourners and easy to see the




Figure 1 Office of the Dead.
Photograph supplied by, and used with permission of, The Bodleian Library,
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b) Geoffrey Chaucer (c. 1340 - 1400) and The Canterbury Tales.
The Canterbury Tales is regarded as one of the greatest books in the English
language, written by an acute and accurate observer. Chaucer was well connected
and well schooled: after school he was hired as a page in the household of the third
son of King Edward III. John of Gaunt, the Duke of Lancaster, was a faithful patron
and protector throughout his life, and when Chaucer, a soldier, was captured in
France during the 100 years war, part of his ransom was contributed by the King
himself. When he returned to England Chaucer was employed by the King on foreign
missions.
Chaucer read widely in Latin, French, Italian and Anglo-Norman. He became
an expert in science, especially astronomy, physics, alchemy and medicine. He knew
senior churchmen and, blessed with a prodigious memory, he quoted frequently from
every book in the Bible. Clearly an intelligent, highly educated and extremely
observant recorder, it is likely that Chaucer was totally familiar with changes in
meaning, nuance and interpretation of words in the languages of his day. Placebo
appears in three of the Tales. As already quoted, it appears in the Parson's Tale,
which was written in prose. It also appears in the Tales of the Summoner and the
Merchant quoted below from a modern English translation (17).
The Summoner's Tale describes the murder of the son of a knight and the
quandry in which the speaker finds himself when advising his friend how to break the
news to the father:
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What should I answer of the knight
His son was stain, there is no more to say,
Dealing with Lords be careful in yourplay:
You sing Placebo! Ishall ifI can,
The Merchant's Tale is a discussion concerning marriage and the perceived
fickle nature of women and wives, between two friends and an elderly knight who
seeks to court a much younger maiden. The two friends are named Justinus and
Placebo, with Placebo clearly a flatterer and sycophant throughout the discussion.
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c) The absent placebo: Chaucer's error of omission?
In the search of the Tales for a mention of placebo in a medical context, there
is a curiosity on a par with the dog which didn't bark and thus attracted the attention of
Sherlock Holmes. In the Prologue to the Tales, Chaucer describes the characters
who are about to undertake the pilgrimage to Canterbury. One of the pilgrims, a
Doctor of Physic, was based on John of Gaddesden who trained at the then world
leading Montpellier School of Medicine, of whom Chaucer states:
He gave the man his medicine then and there.
All his apothecaries in a tribe
Were ready with the drugs he would prescribe.
And each made money from the other's guile,
In extolling the virtues of the Doctor in the Prologue Chaucer includes a
promotional twist by listing John of Gaddesden among the classical physicians with
whose work the Doctor of Physic was familiar, but there is no mention of placebo in the
drugs that were prescribed. In itself the Physician's Tale is a story of unrequited love
between another old knight, an untrustworthy judge and another young maiden, and
contains no medical information and no mention of treatment or placebo.
With his knowledge, erudition, language skills, foreign travel, contacts and
remarkable memory, it seems to me very unlikely that Chaucer simply overlooked, or
forgot to mention the medical use of placebo, if this had been introduced into medical
practice by this time. It is also likely that John of Gaddesden would have been familiar
with placebos, and mentioned them to Chaucer, if indeed these were a part of
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medical practice of the time. It is more likely that at this time the concept of a placebo
in medicine simply did not exist.
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III. PLACEBO JOINS THE MEDICAL LEXICON
In fact, it was some four centuries later before the word was to be introduced
to medicine.
a) Dictionaries Ancient
From the beginning it is clear that the arrival of placebo as a noun in the
medical lexicon, was varied and incomplete. A reference to each from the plethora of
dictionaries published in these early years would become repetitive, boring and not
particularly illuminating. I have attempted to follow the changing definitions in the
medical and general dictionaries, concentrating on those changes which I find
significant for the practice of medicine and the development of placebo as a research
tool. Equally intriguing however, are those many dictionaries that I reviewed which
made no mention of the word when others did. Was this an immediate indication of
the arguments and disagreements that have since followed the word?
Placebo was not mentioned in the Latin-Greek medical dictionaries published in
the 16th., 17th. or 18th. centuries, nor in the early German, French, Italian or
Portuguese dictionaries (18). It was not mentioned in the first English language
medical dictionary published by Blanchaart in 1684 (18) and it was not included in the
first edition of Quincy's Lexicon Physico-Medicum (19). Quincy published subsequent
editions of his dictionary with the 9th. edition appearing in 1775, all without any
mention of placebo. In the same year George Motherby published the first edition of
his dictionary and again, placebo was not included (20).
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Ten years later the story changed. In 1785 one of the most famous
dictionaries in the English language, that of Dr. Johnson (21), published its 7th. edition
and in keeping with the previous editions, there was no mention of placebo.
However, in the same year, the 2nd. edition of Motherby's dictionary was published
(22), and this defined placebo as a common-place method or medicine. Two years
later the same definition of placebo appears in the 10th. edition of Quincy's dictionary
(23). Interestingly, in his presentation to the College of Physicians of Philadelphia
(10), Dr. Pepper incorrectly quoted this definition as a common-place method OF
medicine. which altered the meaning considerably. Obviously the problem of
transcription errors which dogged the early Biblical translations remains even with
modern printing techniques.
Two other medical dictionaries (24, 25) published shortly after the appearance
of placebo in the dictionaries of Motherby and Quincy do not mention placebo,
suggesting that the word was still not in common or frequent use in medical practice at
the end of the 18th century. In 1795 an expansion of the earlier definition with an
added note of derision appeared in a revision of Motherby's medical dictionary (26): a
common place method ormedicine calculated to amuse for a time, rather than for any
other purpose. This definition persisted for another edition and was repeated in other
dictionaries of the time until 1803 when Fox, (27) for the first time, clearly defined
placebo as a medicine and toned down the derisive note: I will please: an epithet
given to any medicine adapted more to please than benefit the patient. This
definition was accepted and repeated by a well known Philadelphia physician of the
time in his own dictionary (28) and was also used verbatim by Professor Hooper when
Burt/TITP 21
he revised Quincy's Lexicon in eight London editions and 13 American editions between
the years 1811 and 1841, (29, 30, 31 for example).
From about this time placebo became a fixture in medical dictionaries, almost
all using the same definition as used by Hooper, with some refinements and minor
changes. In 1833 Dunglison (32) defined it as: Placebo: I will please: an epithet
given to any medicine, intended rather to satisfy the patient than to cure the disease.
and stuck to his definition in a 3rd. edition, published in 1842 (33). This definition
enraged Oliver Wendell Holmes, physician, attorney, poet, medical school Dean,
Supreme Court Justice and humorist, and he disagreed so strongly with this definition
that he told a Harvard medical student class ' the learned Professor Dunglison is
hereby requested to apologise for his definition of the word Placebo or expunge it from
his Medical Dictionary.' (34). This is one of the earliest times that we get some
indication that placebo was being used in medical practice and that this use was not
received with universal approbation. Further indications of disquiet with the earlier
definitions came from Hooper himself for in his last revision of Quincy (35), he
expanded his definition: An epithet given to any medicine administered rather to
amuse the mind of the patient than to fulfill any definite therapeutic intention. Itmust
not be supposed that such administrations are useless: the sensorium often exercises
great influence on disease.
Although the author of an English publication (36) took issue with part of the
definition, seeking to correct the Latin translation: Placebo: Literally, though
incorrectly, I will piease, applied to any medicine given to please or humor the
patient, it seems that medical dictionaries published for the next century continued to
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use the definitions that differed hardly at all from the earlier ones. For example,
Dunglison's son, also a physician, undertook a revision and enlargement of his father's
Dictionary (37) but disregarded Flolmes' request and retained his father's definition of
placebo unchanged. Another popular English language medical dictionary (38) again
slightly modified the definition: Placebo: a medicine adapted rather to satisfy, than to
benefit, the patient. (L. I will please). These many minor variations are reviewed in
great detail by Shapiro (18) and they show a consistent pattern, sometimes with an
embellishment such as the identification of the formulation of the placebo, -'water
colored with cochineal'. However, there is one further definition from the end of the
19th. century (39) which merits consideration because it offers the first suggestion that
placebo was considered to be devoid of pharmacological activity; a make-believe
medicine, sometimes administered for its effect on the patient's imagination rather
than because it is ofmedicinal value.
There is no doubt that by the end of the 19th. century placebo was firmly
established in the medical lexicon and in medical practice and for the first half of the
20th. century it would seem that no major change took place. Nevertheless, there
were differences in the way in which medical dictionaries defined placebo, giving hints
that some authorities were nor entirely satisfied with then current interpretations.
b) And modern
In the early part of the 20th. century there were published in the United States
three medical dictionaries whose modern descendents are published today. The first,
by Dorland (40), followed the previous definitions of placebo as : a medicine given to
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please and gratify the patient. The next dictionary, by Stedman (41), provided the
definition: an indifferent substance in the form ofa medicine, given for the moral or
suggestive effect, and this remained in the next 19 editions. Perhaps the most
interesting definition was in the Medical Digest of Taber (42): Placebo, inactive
substance given to satisfy patient's demands for medicine: such as bread piUs. This
was the first occasion in a medical dictionary that placebo was limited to inactive
substances although Webster's, a non-medical dictionary (43), had used the same
definition some four years earlier: a medicine, or preparation, especially an inactive
one, given merely to satisfy the patient. It is also worth noting that the lawyers had
become involved (44), with their own definition an inertmedicine given to please and
satisfy a patient who thinks medicine is required. In 1947 Dorland (45) republished
the definition used by Foster: a make believe medicine given to please and gratify the
patient, and in 1949 Blakiston (46) provided: a medicine having no pharmacologic
effect, butgiven for the purpose ofpleasing or humoring the patient.
The next significant and totally different definition came from the 22nd. edition
of Dorland (47) which introduced the concept of placebos in research: an inactive
substance orpreparation formerlygiven to please orgratify a patient, now also used in
controlled studies to determine the efficacy of medicinal substances. A decade later
Stedman (48) expanded and clarified this: an inert compound, identical in appearance
with material being tested in experimental research, where the patient and the
physician may or may not know which is which.
After this time definitions in medical dictionaries became more or less
standardised, although many of the non-medical dictionaries maintained the earlier
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religious definitions and meanings in addition to the secular ones. Webster's the
oldest, largest and most widely quoted American dictionary (49), currently offers three
definitions:
a) In the Roman Catholic Church, the Vesper hymn for the dead.
b) A medicine, given mainly to humor the patient, a preparation containing no
medicine but given for its'psychological effect.
c) Something said or done to win the favor of another. To sing Placebo: to
agree, to humor someone by agreeing. [Archaic].
The Oxford English Dictionary, largest and most comprehensive dictionary of the
English language (50) offers four definitions, in chronological order of the appearance
of each meaning:
Placebo [a L. I shall be pleasing or acceptable. 1st. sing. fut. indicative of
placere].
a) Ecci. The name commonlygiven to Vespers in the Office for the Dead.
b) In allusive phrases: to piay the sycophant, flatter, be servile or time
serving.
c) A flatterer, sycophant, parasite. In Chaucer as a proper name.
d) Med. A substance or procedure which a patient accepts as a medicine or
therapy but which actually has no specific therapeutic activity for his
condition or is prescribed in the belief that it has no such activity.
The most recent edition of Dorland's (51) has considerably expanded the
medical definition in line with modern conceptions of the placebo: any dummy
treatment: originally, a medicinal preparation having no specific
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pharmacological activity against the patient's illness or complaint given solely for
the psychophysiological effects of the treatment; more recently, a dummy
treatment administered to the control group in a controlled clinical trial in order
that the specific and nonspecific effects of the experimental treatment can be
distinguished - i.e. the experimental treatment must produce better results
than the placebo in order to be considered effective.
Active p. inactive p. a substance having pharmacologic properties that are not
relevant to the condition being treated.
Finally, the latest edition of Stedman's (52) provides two definitions, the second of
which relates directly to the use of placebo as a research tool:
a) An inert substance given as a medicine for its suggestive effect.
b) An inert compound identical in appearance to material being tested in
experimental research, which may or may not be known to the physician
and/or patient, administered to distinguish between drug action and
suggestive effect of the material under study. SYN. Active p. [L. I will
please, future ofpiaceo].
I find it interesting that even the modern definitions continue to refer to placebo
as a treatment and as a medicine, while clarifying its role in research activities. Is this
meant to indicate that the use of placebo as a treatment continued as the 20th. century
closed?
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IV. THE PLACEBO AS TREATMENT IN MEDICAL PRACTICE
a) The 19th. and early 20th. centuries
In 1892 The Principles and Practice of Medicine, written by Sir William Osier
(53), became the standard textbook of medicine, yet only 10 percent of the entire
book dealt with treatment. This was not willful therapeutic nihilism but a reflection
that practitioners of the day had very few practical choices. Most of their treatments
were symptomatic remedies of herbal origin, largely inactive and ineffective, a view
shared by another influential physician of the time. In his address to the
Massachusetts Medical Society (54) Oliver Wendell Holmes made his famous criticism
concerning ' the whole materia medica, as now used, ' but he did not call them
placebos, even though he had railled against the definition of the word in Dunglison's
dictionary. Of course, not all the drugs of the time were ineffective. For example,
synthetic derivatives of the Poppy, Cinchona and Willow form a major part of modern
therapeutics and one of the more enduring of medical advances was the discovery in
1775, by country doctor William Withering, of the action of digitalis when taken as
Foxglove tea (Figure 2) in curing dropsy. Although Withering recognised the effect he
did not identify the inotropic mechanism of action: even so, it is hard to understand
why one hundred years later Holmes told his Harvard class that 'Digitalis has gone out
of favor.' (55). Perhaps he was expressing frustration at inconsistent formulations and
doses, but even if it fell out of favour with the physicians of that time, the drug has
undoubtedly returned to favour and today remains an important part of our materia
medica.
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Figure 2 Purple Foxglove (Digitalis purpurea)
Personal photograph from the Herb Garden of the
College of Physicians of Philadelphia.
Given the state of medical knowledge in the 18th. and 19th. centuries it was
probably prudent to believe that the treatments were effective drugs and that the
placebo was something else. Thomas Jefferson, the 3rd. President of the United
States, for example, criticised what he called the pious fraud of bread pills, coloured
water and ash pills (56) so it would have taken a courageous and very secure
individual publicly to categorise the remedies of the day as placebos.
One such was Austin Flint, Professor of Medicine at the Bellevue Hospital
Medical College in New York for whom the unusual soft cardiac diastolic Flint Murmur is
eponymously named. Flint described what is probably the first assessment of sham
treatment when he wondered if the current drugs used for treating rheumatism had
any effect on the natural course of the disease. Thirteen of his patients 'Were placed
on the use of a placebo which consisted, in nearly all the cases, of the tincture of
quassia, very largely diluted. This was given regularly, and became known in my
wards, as the ptaceboic remedy for rheumatism. The favourable progress of the
cases was such as to secure for the remedy generally the entire confidence of the
patients.' Placeboic in italics, and the English spelling of favourable appear as such in
the original reference. Interestingly, this paper, which does not mention placebo in
the title, was published posthumously, a year after Flint died (57). Coincidence,
publication delay or to escape criticism? In Britain also, some were openly talking
about placebo and in a popular textbook published a few years later, the authors
discuss the treatment of pyrexia using a simple febrifuge and dismiss this as 'probably
a mere placebo, but there is every reason to please as well as cure our patients.' (58).
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In a review of medical practice in New York around the 1860s, Rosenberg (59)
acknowledges the 'routine use of placebos by practitioners in this period.' Others,
however, were less comfortable and in 1885 an editor wrote (60) 'Physicians and
intelligent laymen know that the former cannot always tell the plain facts to a patient
without injuring him. It should be the rule of his life however, to be straightforward
and candid. Therefore we say that placebos should be, and need be, rarely
prescribed.' He also commented that physicians should 'not find it necessary to keep
a polychromatic assortment of sugar pills in his closet.'
Perhaps the most impressive and courageous review of the role of
placebo up to this time came at the end of 1902 in a lecture given to the prestigious
New York Academy of Medicine by a highly respected Harvard Professor of Social Ethics
who admitted that he had often used placebos in treating his patients (61). In his talk
Cabot reviewed both the good and the bad aspects of placebos in medicine, and given
the setting, the role and the status of the speaker, it is worth considering his
comments in some detail. He started by stating 'I approach the subject of truth in
medicine, not from the point of view of scientific method, nor of metaphysic analysis,
but of professional ethics.' Then in a way which could not be contemplated today he
lambasts two physicians, Drs. Munyon and Trutt, for their cancer cures, cures for
weakness and all-healing handkerchiefs sent through the mail. I could find no
response, riposte or defence from either of the named physicians in subsequent issues
of the journal in which Professor Cabot's lecture was published, so maybe his
comments were accurate and valid!
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Turning to placebo Cabot states: "Now I was brought up, as I suppose every
physician is, to use placebos, bread pills, water subcutaneously, and other devices
for acting upon a patient's symptoms through his mind.' He accepted that the
frequency of placebo use would depend on the individual practitioners, but doubted "if
there is a physician in this room who has not used them pretty often.' No challenge to
this statement by the audience is recorded. Then he shifts his position a little, as if
preparing for criticism of his comments. "No patient whose language you can speak,
whose mind you can approach, needs a placebo. I give placebos now and then (I
used to give them by the bushel) to Armenians and others with whom I cannot
communicate, because to refuse to give them would create more misunderstanding, a
false impression, than to give them. If an interpreter is available I tell no lies in the
shape of placebo.'
Well into his talk, Cabot starts to review the other side of placebo use. "It
never occurred to me until I had given a great many placebos that if they are to be
really effective they must deceive the patient. I had thought of them simply as a
means of getting rid of a symptom and no more a lie than hypnotism or any other form
of frankly mental therapeutics.' He stressed that in order for a placebo to work the
patient must believe in it, but he cautioned that giving a placebo is "...a form of
deception which if detected will destroy the patient's trust in the physician.' He gave
an example from his own practice where a patient saw him preparing water for
subcutaneous injection as a sedative, and asked "How am I to believe anything you
say from now on?' He then asked, is it acceptable to use a placebo if one is not found
out? Answering his own question he continued, "The majority of placebos are given
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because we believe the patient will not be satisfied without them. He has learned to
expect a medicine for every symptom, and without it he simply won't get well.' In this
statement Cabot was echoing Wendell Holmes (54) who spread the blame more evenly,
'Part of the blame for over-medication must, I fear, rest with the profession, for
yielding to the tendency to self delusion, which seems inseparable from the practice of
the art of healing. Another portion of the blame rests with the public, which insists on
being poisoned.'
Finally, Cabot generalises: 'It is we physicians who are responsible for
perpetuating false ideas about disease and its' cure.' He offers another evil of the use
of placebo as giving the patient the harmful idea that every symptom can be cured with
a drug: thus it is impossible to convince the patient of that 'most fundamental
principle of therapeutics - to remove a symptom remove its cause.'
Four years later Cabot (62) returned to the subject of the use of placebos with a
presentation at the Annual Meeting of the American Medical Association, and on this
occasion he was more critical of their use. ' the educated physician gives his drugs
as placebos. In my opinion, the placebo habit does more harm than the habit of
giving drugs to every patient with full faith in their pharmacologic action.' And again,
'Placebos have another bad result. They weaken the confidence of the patient in the
physician, because every placebo is a lie, and in the long run the lie is found out.'
Finally, 'Placebo giving is quackery.'
Following this presentation by Cabot there was a lively discussion from the floor
which the Journal editor saw fit to print immediately following Cabot's article. Dr.
H.A.Hare of Philadelphia 'vehemently denied the truth of any statement made that
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members of the medical profession, particularly of Pennsylvania and of Philadelphia,
had deliberately given placebos to patients with the idea of fooling or deluding them.'
Another speaker, Dr. Cohen asked for the 'intelligent use of drugs, that is to say, the
use of known drugs under suitable conditions.' A statement that is hard to criticise
today!
From the comments of the various sources quoted above it would seem
that the placebo was well recognised and widely used in medical practice during the
latter half of the 19th. century and the first half of the 20th. century, even if most
practitioners did not talk or write about it. In 1938 at the American College of
Physicians meeting in St. Louis, Houston (63) gave an extensive review of placebo use
in medical practice. He identified three types of placebo, that which is an 'effective
drug sometimes', 'The second sort of placebo, the type which the doctor fancies to be
an effective medicament, but which later investigation proves to have been all along
inert, is the banner under which a large part of the past history of medicine may be
enrolled.' And the third which is 'believed in by the physician'. Perhaps Dr. Hare was
deceiving only himself when he made his comments.
b) A passing glance at homeopathy
Founded by C.F.S.Hahnemann (1755 - 1843) this system of therapy is based on
the principle that a medicinal substance giving rise to certain symptoms in healthy
individuals may be effective in the treatment of those illnesses that produce the same
symptoms. Although not strictly a part of any discussion on placebo I was able to find
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comments on homeopathy from two of the physicians and authors already mentioned.
Wendell Holmes (64) stated 'So long as the body is affected through the mind, no
audacious device, even the most manifestly dishonest character, can fail of producing
occasional good to those who yield it an implicit or even partial faith.' A few years
later in his textbook, the younger Dunglison (65), who refused to remove from his
father's dictionary the definition of placebo despite the call from Holmes, wrote, 'I
consider the doses ordered by the homeopath are too small to be of use.' And later
on, 'Can a medical man honestly meet a homeopath in consultation? To this I can
only say, certainly not.'
These show the disdain in which two physicians held homeopathy, at a time
when most of their own prescribed medicines were of doubtful consistency and
efficacy, yet neither author labeled the homeopathic treatments placebo. Might they
have recognised that placebo therapy had some utility and was widely used by their
colleagues in the medical profession, whom they would not wish to expose or
embarrass?
c) After the Second World War.
At this stage two important events occurred, the start of 'The Therapeutic
Revolution' which produced new drugs and the Declaration of Helsinki which provided
guidelines for patient protection in treatment and research. For the first time there
were available drugs that were consistently potent and effective and these had to be
evaluated and compared with existing therapies which entailed patient enrollment in
clinical trials. Placebo still played a major role in therapy as evidenced by the
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increasing number of publications that discussed the role and use of placebo and
practitioners seemed more willing to discuss their use of it. Pepper (10) called
placebo 'a valuable item of our therapeutic armamentarium.' As Dr. Pepper practiced
in Philadelphia, was a highly regarded teacher and clinician who also was President of
the College of Physicians of Philadelphia, the oldest society of that ilk in the United
States, his comments cast some doubt on the validity of Hare's earlier vehement
denials to Cabot. In addition to his accolade to placebo, Pepper supported Cabot
saying 'Every one of us has often used the word and often prescribed the placebo, yet
how many of us realize how little has been written and how little is known of the
history of this word and this type of treatment.'
In contrast to the paucity of papers on the subject in the first half of the 20th.
century, the second half has seen a plethora of publications on placebo. Among the
earliest was a conference sponsored by an Ivy League University with a major
academic medical school ( 66). The conference was opened with Dr. H.G.Wolff
describing the placebo as a Very important therapeutic device' while Dr. E.F.DuBois
lamented that They have been considered the humblest, the most unscientific and the
most dishonest of drugs.' There followed a lengthy series of case and anecdotal
reports from several speakers, all laudatory, describing the success of placebo, its
importance in their practice and giving advice on the patients who might best respond.
In summarising the conference the Chairman gave three conclusions: there was
general agreement on the utility of placebo in practice, there was disagreement on the
best agent to use and that successful management with placebo depended on the
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proper selection of cases and choice of placebo material. Clearly no reticence on the
part of the practitioners here.
In the same year Piatt (67), who would become President of the Royal College
of Physicians, was in turn scathing and accepting of placebos: The frequency with
which placebos are used varies inversely with the combined intelligence of patient and
doctor.' followed by: The point is that the prescription of a placebo should be a
deliberate act and not a conditioned reflex, and it should be an invariable rule that it
must be something which can do no good.' Again, 'It must be clearly understood that
a placebo is given for the mental comfort of the patient, not of the doctor, and that
whereas it may occasionally be expedient to deceive the patient it should never be
done at the risk of deceiving oneself.'
An Editorial in the British Medical Journal (68) quoted a family practitioner who
found that 10% of general practice patients were treated with placebo and added
There is no question about the usefulness of placebos in therapeutics, nor about the
fact that they have in some cases a more powerful effect than known pharmaceutical
agents.' The writer heaped on more praise pointing out that there are 'many real
symptoms and diseases in which placebo is often justified and works wonders.' Not to
be outdone Lancet, perhaps detecting the start of a shift against placebo stirred the
controversy with two papers a few years later. Carter (69) discussed the use and
abuse of the placebo and warned against prescribing the placebo to please the doctor
rather than the patient. He then showed his support with his final statement,
'Nevertheless there is a not inconsiderable place for placebo in medicine and, if
intelligently used, I will defend it to the last drop in the bottle.' This was followed by
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another senior British physician (70), who was less enthusiastic and wondered why
'placebos are so widely used - are placebos part of the Art of medicine or a necessity?'
He saw the placebo as 'a form of deceit initially of the patient ultimately of the doctor.'
But like Piatt he found for placebo a 'small place when no effective treatment is
available, and for re-inforcing patient confidence in his recovery.' Presumably so long
as the patient did not discover the deceit! Not every one agreed with these
sentiments and two highly critical Letters to the Editor were published in the next
week! (71, 72).
American physicians were also providing support. Findley (73) thought that
placebo 'should be accorded more respect than it gets. For the vast majority of his
patients it and himself are all that the modern physician has to offer.' a statement that
showed an understanding of the placebo effect as well as the placebo itself. Earlier,
an American textbook (74) noted that 'The most frequent method of psychotherapy is
the giving of placebos.' adding '....giving the placebo is at least a recognition that the
patient is suffering and the patient appreciates and gets better out of gratitude. The
physician who prescribes placebos, in whatever form, is not consciously dishonest.'
Leslie (75) quoted Plato 'A lie is useful only as a medicine to men. The use of such
medicines should be confined to physicians.' and he also believed that 'deception is
completely moral when it is used for the welfare of the patient.' He drew a fine
distinction between deception and deceit and offered that if deception was to be used
then it must be wholehearted and efficient. He believed that 'there are circumstances
where placebos constitute the therapy of choice .' He even offered advice on the
types, appearance and formulations of placebo to be used.
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In 1970 an Editorial (76) again took doctors to task for 'failing to make
effective use of the considerable body of scientific evidence on the placebo effect,' and
added There may be many occasions when an appropriately presented placebo will be
less harmful and perhaps more beneficial than a complex and incompletely understood
drug.' The writer also lamented that there was 'little evidence that placebos were
being employed in a systematic way.'
i) Personal experience
Whether or not these comments encouraged the use of placebo as
treatment is not recorded, but I know from personal experience as a medical student,
when I followed tradition by taking locum tenens appointments for medical and surgical
residents who were on vacation, and then as a House Officer, that placebos were
commonly used as sedatives at the Edinburgh Royal Infirmary in the late 1950s and
early 1960s. In the bustle and noise of the wards many elderly patients had difficulty
falling asleep at night, even when sedatives had been prescribed and given to them.
At such moments it was routine for nurses to give these patients one or two tablets of
vitamin C, together with the assurance that these were effective sedatives, and they
nearly always fulfilled the promise. In part, the deception was justified by the nurse's
knowledge that additional doses of barbiturate, the most widely used sedative at that
time, carried risks which a tablet of vitamin C did not, but the active sedatives also
required a prescription which entailed finding the physician to write it. Vitamin C was
quicker, easier and apparently just as effective! It is worth pointing out that because
vitamin C did not require a prescription or written hospital order there was no record of
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its use and although the practice was common knowledge among the Residents we did
not have to admit to the deception which we condoned. I suspect that we were not
unique among the medical profession in this respect.
ii) Practice in general
Thomas (77) has suggested that by the end of the 20th. century
placebos were deliberately given only rarely as treatment, and he offered a possible
explanation that this may be a result of the association with charlatanism. He went on
to describe a study which he undertook (78). In 1,656 of 3,848 patients seen in
general practice, no firm diagnosis could be made. These patients all had a
consultation and discussion of the complaint, received a physical examination and
reassurance that there was no serious illness and that they would soon recover. Most
patients received a placebo, a few received nothing at all, yet at the follow up visit
82% claimed to have recovered.
That deliberate use of placebos for real life treatment was still practiced towards
the close of the century was accepted by a pharmacologist (79) although, like
Houston (63), he made the point that some of this may arise because the physician
innocently believed that the prescribed drug possessed the relevant pharmacological
activity when it didn't! This would fit with the third type of placebo already discussed
(63). Even after the close of the 20th. century a rheumatologist has described (80)
the successful treatment of osteoarthritis in a patient for whom modern conventional
therapy had failed to provide relief, using golden raisins soaked in a particular brand of
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Bombay gin. However, I believe that this would not qualify as an inert placebo devoid
of any pharmacological action.
Modern textbooks offer mixed advice on placebo use. In 1982 one textbook
(81) informed its readers that 'Placebo effects are important' but did not advocate the
actual use of placebo. Instead the authors emphasised that the physician's
enthusiasm and reassurance were important. Another major textbook from a year
later also concentrated on the placebo effect pointing out that approximately one third
of patients obtain benefit for a variety of illnesses when given therapeutically inert
substances (82). Ten years later another edition of the same textbook fails to mention
placebo or placebo effects, at all (83). In the United States The Merck Manual has
been in continuous publication since 1899 and the pocket sized convenience makes this
probably the most widely used medical reference text. Several modern editions refer
to the placebo, discussing the nature of placebo effects and also the deliberate use of
placebo in treatment (84, 85). The Centennial edition (86), however, while retaining
most of the text from the earlier editions, has dropped the deliberate use of placebos,
pointing out the deceptive nature of this use and the harm that can accrue if the
deception is discovered. Mention is made of the practice of prescribing, say vitamin
B12 injection, when this clearly has no relevant therapeutic benefit for the patient,
noting that physicians would not prescribe sterile water for injection. If the patient is
informed and agrees the authors suggest that placebo could be used as a diagnostic
tool in particular circumstances. Placebo effects are also discussed in most recent
edition of the first textbook on Clinical Pharmacology (87) with the comment that these
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effects can be exploited to supplement pharmacological effects and thus represent the
difference between success and failure of therapy.
So, at the end of the 20th. century does placebo have any role at all? Clearly
there are different opinions and several authors have suggested that even with modern
medicine occasionally we will need placebo as a treatment. Thus some can justify
using a placebo under certain circumstances while others decry its use under any
circumstances. Is only one choice correct or does some of the confusion arise from
misunderstandings of what a placebo is and how it performs: can modern medicine
and research actually afford to do without a placebo? I believe not and from this point
offer my thesis as to why placebo is still an essential and indispensable part of the
modern medical research scene.
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THE PLACEBO AND THE PLACEBO EFFECT
Setting the Scene
From this review of the history of placebo and the many definitions that have
been created it is easy to see that there can be disagreement and misunderstandings.
An Editorial in Lancet (88) referred to placebo as not quite respectable in the context
of treatment and the modern connotation of placebo is one of disdain, harking back to
the Middle Ages. Hardly surprising that placebo has wound up as an object of derision
and embarrassment.
Could the reason be, as Leslie has suggested (75), that modern medicine has
become so concerned with scientific advance, the growth of Evidence-Based Medicine
and cost driven efficiencies, that too little attention has been paid to the Art of
Medicine? Thus, for most practitioners the knowledge, understanding and application
of placebo has not advanced and there is confusion between the placebo and placebo
effect.
If the case is to made that placebo is an essential research tool in the process of
drug evaluation then it is equally essential that the confusion and misunderstandings be
dispelled and replaced with consistent interpretations.
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V. WHAT KIND OF PLACEBO?
a) Active or impure
When physicians today talk of using placebo treatment they are usually thinking
of one of the types described by Houston (63) or along the lines defined by Shapiro
(18) as 'any component of therapy deliberately used although it is without specific
pharmacological activity for the condition being treated.' This component may be,
say, tablets of vitamin C or injection of vitamin B12, both of which have clearly defined
inherent pharmacological activity but lack specific therapeutic activity against the
disease or illness in question. It may also be the use of a drug that is effective in the
required therapeutic area, but given at a dose that is known to be ineffective. These
are generally referred to as an active or impure placebo.
b) Inert compound
It is important to distinguish the active or impure placebo from the inert
placebo, used in clinical research studies. These specially formulated preparations are
compounded from inert ingredients such as lactose, starch, isotonic physiological
saline or sterile water. Once formulated they are presented as tablets, capsules,
ointments, creams or solutions for injection that are identical in appearance to the
comparator drugs being evaluated in the double blind (also called double masked)
studies.
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c) Selecting the placebo
Advice has been offered by several authors (75, 89, 90, 91) as to the most
effective formulations for maximizing the effectiveness of the placebo. Route of
administration is important: although intravenous injection provides the most
impressive psychotherapy with intramuscular injection next in order, in most instances
the oral route is preferred for simplicity and convenience. Tablets and capsules should
be shaped and coloured red, yellow or brown, should taste, smell and look like
medicine and should not look like tablets or capsules that are available at the pharmacy
without a prescription. It seems as though green tablets are the most effective
anxiolytics, yellow tablets work best in depression (92) and round white tablets tend
to be the least effective in all situations. Tablets should be either tiny, implying great
potency, or very large, impressive for size alone. Finally, the chosen placebo must
never be toxic or noxious, the objective being to help, not harm, the patient.
Cutaneous application of placebos can be made more impressive by
incorporating some dissolved substance such as Epsom salts or magnesium sulphate,
which although not absorbed through intact skin, cools as it evaporates. Patients with
coryza or blocked sinuses often seek relief by inhaling steaming water containing
tincture of benzoin. Even though it is only the steam which is therapeutic the smell of
benzoin adds verisimilitude. If these suggestions seem facetious or cynical that was
not the intent. The placebo effect is a multifaceted phenomenon of which the placebo
formulation is but one component, and the spectrum of efficacy of placebo is
extremely susceptible to manipulation by outside factors, as we shall see.
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Nevertheless, the drive for science in medicine has led to attempts to explain how an
inert or impure compound might actually produce a pharmacological response.
d) A possible mechanism of action
......we are not ourselves
When nature, being oppress'd, commands the mind
To suffer with the body.
King Lear, Act II. 4.
William Shakespeare, 1564 - 1616.
To attempt to explain the mechanism of action as through the mind at first
sounds trite, dismissive and even patronising, yet this was the explanation given in all
seriousness by Hooper (35) in his last, expanded definition, while Holmes (64) in his
dismissive comments on homeopathy also acknowledged the importance of the link
between mind and body.
Placebo produces the best effects when used in patients with illness of a
subjective nature, particularly pain, disorders of autonomic sensation such as nausea,
anxiety, depression and phobias or in disorders of factors under neurohormonal control
such as blood pressure and bronchial air flow (93). Beecher (94) described the two
phases of pain, the original sensation (nociception) and the patient's reaction
(awareness and cognition) and pointed out that placebo modifies only the second,
cognitive, phase which may reside in the thalamus (95). Anxiety activates the
hypothalamic-pituitary-adrenal (HPA) axis and increases the perception of pain while
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removal of anxiety decreases pain. Anxiety also increases blood pressure in a
conditioned response that has been described as White Coat Hypertension (96).
The suggestion that placebo might actually have an identifiable pharmacological
action followed the demonstration by Lasagna and others (97) that naloxone, a potent
opioid antagonist, had hyperalgesic effects in humans. Subsequent studies in animals
identified a group of endogenous opioid peptides (often referred to generically as
endorphins) in the brain, and showed that these mediated some types of somatic pain
(98). Later, these endogenous opioid peptides were linked with regulation of the HPA
axis although the precise manner in which these links function remains unclear (99).
Using the dental pain model Levine et al. (100, 101) found that patients who
received naloxone reported significantly more pain than did those who received
placebo. Also, the patients who obtained pain relief from placebo given first, had an
increase in pain level following an injection of naloxone whereas patients who did not
have an analgesic response to placebo when given first, did not get an increase in pain
level following naloxone. These findings led the investigators to postulate involvement
of endogenous opioids in the human placebo response. At the time these studies were
criticised (102, 103), and other investigators (104) produced conflicting results, but a
recent systematic review of six published studies (105) has concluded that the
endogenous opioids do have a role in placebo analgesia. Whether or not the
endogenous opioids are involved in the mechanism of placebo analgesia this does not
necessarily explain the mechanism of placebo effects, as Wall has discussed (106).
This lack of a clear cut explanation as to how or why placebo works is a
disappointment to those who demand a science based justification for their actions.
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For these scientists the unexplained mechanism makes placebo an embarrassment but
it is worth recalling the experience of William Withering with digitalis. He knew that
digitalis worked, he just didn't know how it worked. Perhaps the earlier comments
and definitions on the mechanism of placebo were closer to the truth than we
recognise. Our science has made clear that so far we barely understand the workings
of the brain and the extent of brain-body interactions, so perhaps we should accept
that as yet we cannot explain the mechanistic conundrum of the placebo itself and
examine instead the response to placebo, the so called placebo effect. Separating
these two is something that leads to continuing confusion and misunderstanding.
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VI. THE PLACEBO EFFECT AND ITS COMPONENTS.
a) The placebo effect, or response
Even if it is not yet possible to satisfy the scientific demands for an explanation
as to how the placebo exerts its effect, at least it is possible to understand how and
why these effects, or responses, may be brought about. The placebo effect is a
multifaceted, multicomponent response, of which the placebo itself is but one
component.
Conditioning gives priority to learning from direct experience (107). In the
classical experiments of Pavlov, the dogs started to salivate at the sound of the bell
and before they could see the food container, because they had learned from
experience that the tintinabulation was always followed closely by the arrival of food.
This was a typical conditioning response. Expectation, on the other hand, requires a
cognitive appreciation of the information which is then processed and organised for
future reference Expectation places priority on the importance of verbal conditioning
(108).
Conditioned enhancement of the analgesic response to placebo, based on
direct experience, has been shown to be greater and more important than expectancy,
and that these conditioning responses can occur even when no placebo is given (109).
An analgesic study (110) and a study in patients with hypertension (111) have shown
that the response to the first drug, or dose, influences the response to the second
drug, or dose, and these are examples of the conditioning effect. While conditioning
from direct experience is a potent means of enhancing the effects of an intervention
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intended to reduce pain, it has been shown that there is also an expectancy
interpretation of the conditioned response and that expectancy plays a role in
potentiating the placebo effects (112).
Clearly there will be many more investigations into the psychological role of
conditioning and expectation and the impact these have on the placebo effect. It is
likely that both will be found to be important and possibly combined in most instances
but it is not part of this thesis to examine the interaction further. I included this part
only because I believe that to understand the role of placebo as a research tool it is
necessary to understand how and why the placebo response occurs. A review of the
components of the response, which include faith, previous experience, learning,
reputation and expectation, will show how these interact to produce conditioning and
expectation. The placebo effect, or response, is variable and inconsistent between
different patients and within the same patient at different times and circumstances,
changing synchronously with changes in the components, recent experience and
further learning, changing expectations and reputations. At any one time it is a
complex amalgam of interactions between the patient and the physician. Beecher
(113) commented that 'However inert a placebo may be in the usual physical sense, it
is not inert in its effect.' while Kabler (114) wondered whether placebo, which has
produced objective physiological responses when used to treat patients, can truly be
called inert? He concluded that while a placebo may be inert people are not. To
which can be added with confident assurance, and neither is the physician!
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b) The patient and faith in the healer
Faith in the healer is probably the major and most underrated component of the
placebo effect. In our society this faith has been inculcated since infancy and our
history is replete with tales of miraculous cures or healing.
One of the earliest reports of this faith and a miracle cure comes from the
Gospels and tells of the woman who had uncontrolled haemorrhage for 12 years. She
had consulted physicians and St. Mark was highly critical of the way in which she was
made to suffer at their hands. St. Luke, himself a physician, probably understood the
medical difficulties better and was less critical, confining himself to noting that she had
spent all her money on the physicians without being cured. The woman had heard of
the miracles performed by Jesus and she was cured merely by touching his garments
as he walked. Greenblatt, a professor of endocrinology, has noted (115) that
although functional uterine bleeding can readily be explained scientifically as a
disturbance of pituitary-ovarian balance, psychosomatic disturbances play a role in
uterine bleeding more frequently than is commonly acknowledged. He notes also the
words of Jesus to the woman, 'Daughter, be of good comfort: thy faith hath made
thee whole: go in peace.' These produced such a degree of faith that the cessation of
the woman's bleeding was more rapid than can be induced by progesterone today.
In the Middle Ages this faith was transferred to people of high standing or
ecclesiastical position, and monarchs in particular (116). The disease known as
scrofula or The King's Evil, was in fact cervical tuberculous adenitis and it was
supposed to be cured by a touch from royalty (117). The Monarch's, or Royal, Touch
was practiced in France by Philip I but it was Edward the Confessor (1006 - 1066)
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who first adopted this form of therapy in England and the Monarch's Touch was
accompanied with great ceremony. Buchanan (118) notes that James VI (1603 -
1625), who united the kingdoms of England and Scotland and commissioned the
Authorised translation of the Bible, was sceptical of this traditional practice. Charles II
(1660 - 1685), supported by his personal surgeon Richard Wiseman who affirmed his
belief in the therapy, set aside one day in the year to touch those afflicted with
scrofula. Holmes (64) while mentioning the practice by Edward the Confessor pointed
out that William III (1689- 1702) abandoned the practice completely. However, his
successor, Queen Anne (1702 - 1714) who was the daughter of James II and the last
of the Stuart monarchs, reinstated the practice, and with some success, for it is
recorded that she cured the scrofula in a young child who grew up to be Dr.
Samuel Johnson of Dictionary fame. Surely a reliable recorder of the event even
though he would not be able to confirm the accuracy of the original diagnosis? Our
own establishment of faith started young for who, as a child with a minor knock or
bruise did not trust Mother to 'kiss it better'?
When patients seek medical help in treatment there is already an established
faith based on past experience and in part the patients' responses to a new treatment
will be based on their responses to the success or failure of previous treatments, and
success breeds success.
c) The role of the patient
The psychological components of medical practice and the patients'
expectations should not be ignored or underestimated. Patients with a positive,
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optimistic approach invariably have a better response to treatment than do those who
are fearful or pessimistic. Mira (119) has described the malignant anxiety that
occurred among the civilian population during the Spanish Civil War and which led to
death in a few days. Beecher (120) tells of two surgeons at Johns Hopkins hospital
who refused to operate on any patient who acquiesced in their suggestion of an
operation but then expressed firmly that death would result, and of the Army officer at
Walter Reed Hospital facing surgery for an inguinal hernia who stated that he would die
if operated on. The surgery was uneventful but the patient developed ileus and died.
When his personal effects were collected it was found that he had laid out his dress
uniform and left instructions for his funeral. Beecher makes the point, in italics, that
an 'understanding of the role of these non-specific forces is essential to the full
understanding of the possibilities inherent in the disease situation.'
d) The role of the physician
After the patient, the second most powerful influence on the placebo effect is
the physician and at least one author has described the doctor himself as an important
therapeutic agent (63). More recently a number of authors have emphasised the role
of the physician and identified factors in this role which can affect the overall placebo
response (66, 89, 121, 122). These factors are:
1) the amount of time spent with the patient;
2) the time spent in a careful, thorough examination;
3) the explanations about the disease and the prognosis;
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4) explanation and expectations on the proposed treatment
particularly reinforcing a positive approach;
5) an explanation that dose titration might be required;
6) a discussion of possible adverse secondary effects from
the treatment;
7) ensuring continuity of care;
8) discussing other treatment options, especially if the first
treatment is not fully effective. To this I add an
exhortation of my own, to 'follow the failures' (123); and
9) creating an impression of authority and control over the
situation. The late Dr. Henry Matthew, in his day with
the largest private practice in Edinburgh, used to tell his
patients 'It is probably going to get worse before it gets
better, but we will be able cope.'
The impact of a positive approach, as outlined above, was shown in a study
reported by Thomas (124) when he found that a successful outcome to treatment was
reported by 64% of patients who were given a positive consultation with a firm
diagnosis and treatment plan, compared with 39% of those patients who were given a
negative consultation in which the physician implied some doubt as to the diagnosis
and outcome of treatment.
The instructions outlined above require considerable time to execute properly
and in medicine today, driven by cost effectiveness, the need to see as many patients
as possible in a limited time and the fact that more patients are seeking to see fewer
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physicians, it is doubtful that many physicians can accomplish more than a few of the
suggestions. The importance of the physician's personality has been examined and
explained by Balint (125) and the physician's role in the psychological component of
the placebo effect should not be minimized. A study was undertaken in patients with
bleeding ulcers, all of whom were treated with placebo and all of whom received in the
same words the message that this new medicine would undoubtedly produce relief
(126). In the group of patients who were given the message by the study physician,
70% had excellent results. When the message was given by the study nurse only
25% of the patients reported an excellent result. Every opportunity must be taken to
increase the patient's faith in the physician, the treatment and the outcome and
although these findings are important in practice, more relevantly, they are a critical,
and often overlooked, factor in clinical research. The presence and involvement of
the study physician is supremely important. When study patients are evaluated by
different team members their results tend to be different, which is why the first
statistical analysis is always to look for the presence of inter-observer differences.
e) The environmental impact
Beyond those already considered there are other, often unappreciated,
components of the placebo effect namely the impact of the visit to the physician. The
anticipation, perhaps concern, the waiting room, the medical smell of a hospital or
clinic, the overheard conversations of others reflecting the speaker's faith and
expectations or the reputation of the physician, clinic or hospital. During the
consultation the furnishings and accoutrements of medical practice, the examining
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couch, the scales, the sphygmomanometer, possibly an ECG machine, kidney dishes,
bandages and tapes and those 'special' medical scissors all combine to create powerful
images and build positive expectations.
f) The prescription
At the end of the consultation comes another great placebo effect, the writing
of the prescription. Although no longer yesteryears' impressively arcane, illegible
mystery written in Latin (Figure 3), this remains a potent psychological stimulus.
During the Cornell Conference (66) Dr. DuBois stressed the placebo element of
this activity. A prescription cannot be written without an element of the placebo effect
and a warning has been offered that this task should not be taken lightly (68). It has
the weight of 2,000 or 3,000 years of medicine behind it. The prescription has to be
written by a doctor, it has to be signed by a doctor and it has to be taken to a
pharmacist to be filled, both respected figures representing education, authority and
power. If the prescription is written in a perfunctory way it may have the effect of
increasing the faith in the disease rather than the remedy and the physician.
g) Surgery as a placebo
If a visit to the doctor is fraught with so many opportunities for psychosomatic
overlay and placebo effects then these are eclipsed by the aura and opportunities that
surround the process of a surgical operation (127). Expectations are influenced by
friends, television programs, newspaper reports and magazines, especially with the
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increasing call to publish Rankings listing hospitals in order of death rates from various
surgeries etc.
Figure 3 A prescription from R. Cheston, MD. 1892.
Photograph supplied by, and used with permission of, The Marvin Samson
Center for the History of Pharmacy, Philadelphia University.
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The detailed preliminaries to surgery, preparing for the operation, admission to
hospital and the attention paid by large numbers of people involved in the admission
and preparatory processes, the pre-surgery examinations and assessments, the
unfamiliar anaesthetic room, the anaesthetic and going to sleep, invasion of one's
body and then waking in an intensive care/recovery room with the attendant
monitoring devices, provide a powerful combination of components. No wonder that
Beecher (113), an anesthesiologist not a surgeon (and misquoted by Johnson),
concluded that Tt would be surprising, if in this charged atmosphere, surgery did not
have a powerful placebo action in addition to what it may or may not accomplish
physiologically.' He also went on to examine the different results obtained by the
enthusiastic surgeon as compared with those obtained by the sceptical surgeon.
Enthusiasm on the part of the surgeon was better!
The placebo effects have been shown in unwitting surgical trials as when the
operation had to be halted because of uncontrolled hypotension or because the
surgeon discovered that the disease was so widespread as to make the planned
procedure impractical. Wall reports (90) that there are several such instances where
the patients, unaware that the surgery had not been performed as planned,
nevertheless had an excellent result. Despite the inherent difficulties there have been
a few planned studies conducted to examine the placebo effect of surgery. An
evaluation of the benefit of ligating the internal mammary artery in an attempt to
improve circulation to the heart had patients allocated at random to either artery
ligation or skin incision only, both performed under local anaesthesia (128). The
results showed some benefit for both groups but no benefit for the ligation group
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beyond that seen in the skin incision group. More recently there have been reports of
surgical procedures performed in patients with Parkinson's disease (129). Patients
were allocated at random to have human foetal tissue implanted in the brain or to
undergo the same surgical procedures but without the implant. As might be expected
there were several patients who did not get the implant but nevertheless reported
improvement. Publication of this study was followed by an editorial (130), a series of
critical letters and even merited a report in a newspaper (131). It would seem that
Finneson (132) was absolutely correct when he wrote 'Probably surgery has the most
potent placebo effect that can be exercised in medicine.'
h) No role for placebo in practice
Despite the earlier Editorial exhortations I do not believe that it is ethical to use
a placebo in patient treatment. The major reasons are two, namely the deception
involved and the question of beneficence, and as both are used by critics of the use of
placebo in clinical research they are addressed in more detail in the next Section.
Briefly, patients are autonomous agents, capable of making their own
decisions, deliberating about personal goals and entitled to make choices based on the
information they are given. Deception by the unexplained inclusion of a placebo in
their treatment repudiates the autonomy of the individual. Beneficence requires that
the patients must be protected from harm and their well being ensured. Use of a
placebo could impede early diagnosis of a potentially serious illness for should the
patient respond to the placebo then the physician might be deceived into believing that
the illness had been cured and stop further evaluation or investigation.
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Some physicians (91) claim to use placebo to differentiate between functional
and organic disease, but given the pervasiveness of the placebo response this is a
dubious test and may lead to the problems listed above. Physicians who use a
homeopathic dose of active drug as an active placebo seem to me to be guilty of not
respecting patient autonomy and of ignoring beneficence, in addition to deceiving
themselves. In 1945 Pepper (10) commented that 'giving of a placebo is not to be
mentioned in polite society.' and I suspect that most physicians today would echo his
sentiments.
i) But the placebo response is different
No place for placebo perhaps, but the placebo response is another matter.
This distinction and the component factors making up the response can be influenced
by physicians. A pharmacologist has noted (133) that 'placebo effects are probably
the most relied upon aspects of pharmacotherapy today, however unintentional this
may be on the part of the physician.' This author quotes one of the physicians who
founded Clinical Pharmacology as writing 'The question is not whether the physician
should or should not use placebo, but how he should best utilize the omnipresent
effect.' The British Medical Journal two years later (134) weighed in with 'Placebo
response has served doctors well. Because of it they have throughout the centuries
been held in high esteem, despite the dearth of medicines with beneficial therapeutic
effect.' Although these comments are not particularly flattering to the physicians,
they may have been correct at the time of writing, given the available pharmacopoeia.
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These comments not only have relevance for clinical practice but also
encapsulate the main reason for including placebo comparators in clinical studies
intended to evaluate or demonstrate the effectiveness of new drugs and therapies.
Like the Biblical poor, the placebo effect, or response, is with us always, but not
always consistently. As in clinical practice, it also has an immense, important and
undeniable role in clinical research.
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PLACEBO IN MODERN MEDICAL RESEARCH
The critics attack
It is an interesting anomaly that around the time that some journals were
promoting the rational use and better understanding of placebo and the placebo effect
in clinical practice, criticism of the use of placebo in medical research was gathering
steam. Support for the role and use of placebo was mustered by the publication of a
series of papers (135 -139) and a Conference on the topic reported in the same journal
(140).
Perhaps the most consistent and strident critic has been Rothman, a professor
with academic titles at two Boston Universities (141) but he has not been alone (142 -
146). Although these different critics have their own choice of topics, in general their
criticisms include some or all of the following variants: poorly designed trials, patient
deception, infringement of patient rights and the Codes of Ethics such as the Helsinki
Declaration, problems with informed consent, denial of effective therapy, impact on
benefit - risk equation, putting patients at risk, deleterious effects on the quality of life
and unreasonable demands from the Regulatory Agencies for the evaluation of new
drugs.
Feinstein, a statistician, has commented (147) that many of the critics are
confused about their target and the criticisms are ill aimed, attacking components of
the clinical trial process other than placebo use itself. Perhaps the critics hope that
this shotgun approach will hit at least one target somewhere, but it seems to me that
the best way to defuse the criticisms and make the case for placebo use is to consider
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each logically and attempt to refute it, so I begin with a consideration of the clinical
trial itself, what it is and how it resembles or differs from clinical practice.
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VIII.CRITICISMS AND ANSWERS
a) The clinical trial
A clinical trial is a carefully and ethically designed experiment with the
aim of answering some precisely framed question.
Principles ofMedical Statistics 1971.
Hill, A.B.
Many critics claim that the use of a placebo is unethical in a clinical trial because
the trial is thus poorly designed. Sackett (148) agrees that a badly designed trial is
always unethical and Beecher (149) makes the point that 'an experiment is unethical
or ethical at its inception: it does not become ethical post hoc - ends do not justify the
means.' so there would seem to be no argument on that score. However, this
criticism is aimed not so much at placebo as at the components of clinical trial design,
namely randomisation, the double blind technique and the manner in which the study
results are presented. Critics claim that trials deny the physician the ability to choose
the best treatment for the patient and also infringe the ethical stance that the interest
of science and society must never supercede the well being of the individual patient.
The definition makes it clear that a clinical trial is an experiment: in a trial a
patient with a disease is seen by a physician at a clinic or hospital, but from that point
on there is little resemblance between clinical trials and clinical practice. In fact, trials
more closely resemble a game, played on a designated field, with limits to the number
of players and substitutions, rules governing conduct of play, and the whole under the
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control of referee or umpire who impose penalties for infractions of the rules. Such
penalties have included refusal to accept the study and its results as part of a new drug
application and suspension of investigators.
Clinical trials differ from clinical practice because they limit the physician's
options to those described in the protocol. Only a specific number of patients who
meet all the criteria for inclusion may be enrolled and these criteria usually exclude
patients with concomitant diseases or treatments. Treatment options are limited to
those of the study, commonly two or three different drugs or placebo. Because of the
randomised, double blind design, now the recognised standard for clinical trials and
particularly for evaluations of new drugs, selection bias is minimised because neither
the patient nor the physician knows or can influence which treatment is allocated to the
patient.
The various measurements to assess the patient's response to treatment, the
specific laboratory variables and the times at which they are to be monitored are
specified in the protocol, and are usually much more numerous and frequent than they
would be in routine practice. Finally, the duration of treatment is specified and this
stops at the end of study date whereas in routine practice treatment may be continued
for months or years.
It is correct that at the end of the study the statistical analysis and data
presentation commonly compare the patients' response rates by comparing the values
across the treatment groups, but during the conduct of the study each patient receives
individual treatment and monitoring of an intensity far greater than occurs in regular
practice so I do not see how the interests of science and society are superceding the
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individual's well being. If anything, there is greater care of the individual in a clinical
trial. A decision as to whether the trial is ethical or unethical and an assessment of
risk inherent in the study is made by the Institutional Review Boards in the United
States and the Independent Ethics Committees in Europe.
b) The Institutional Review Board
Critics complain that the institutional bodies set up to oversee and approve
proposals for clinical research have inconsistent and differing standards for assessment,
do not understand the ethical problems with placebo and are failing in their
responsibility to protect the patients.
As reviewed by Levine and Lasagna (150) the impetus for establishing
independent committees came from the first Declaration of Helsinki in 1964. In the
United States this was followed by a memorandum from the Surgeon General (151)
establishing independent review of all grant proposals submitted to the Public Health
Service. Beecher's article (149) exposing 'unethical or questionably ethical
procedures in subjects research' provided further stimulus and was followed by
publication of the Belmont Report which in turn led to the Federal Regulations that now
govern medical research in the US.
In the United Sates the Food and Drug Administration (FDA) have formally
defined (152) the role, functions, composition and operations of the Institutional
Review Board (IRB). The requirements for Independent Ethics Committees (IEC)
proposed by the International Conference on Harmonisation (ICH) are very similar
(153). Under these mandates the IRB/IEC is charged with reviewing the proposed
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study protocol, suggesting changes and ensuring that these are made, assessing
potential risks from the study, ensuring patient protection and conducting periodic,
usually annual, reviews of study progress and recommending changes to the protocol.
Of course, having regulations does not guarantee that they will be
followed and the critics have some validity in their complaints. In the past three years
the Office for the Protection from Research Risks (OPRR) has audited IRBs in the US
and shut down half a dozen academic boards (154). In the main they found that the
boards lacked sufficient evidence to make determinations required for approval of
research proposals and performed inadequate continuing review of research projects.
As a result several members of University staffs were fired or suspended from their
jobs. Critics admit that IRBs are clearly overloaded with protocols for review (155)
but also charge them with unethical behaviour and endorsing unnecessary new
research (156). Others have called for an overall improvement in medical research
standards and noted that the IRB process, imperfect though it may be, is the only
safeguard available in research (157). There have been calls for education
opportunities for the IRB members (158) and also for the setting up of a national
committee (159). In the United Kingdom a two tier system has been introduced in
which regional IEC approval is followed and supplemented by expedited local approval,
but so far the results appear mixed. While there have been some reductions in the
time to get approval this has been inconsistent and offset by increased demands for
paper copies with consequent increased costs (160, 161, 162, 163).
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Clearly there are multiple difficulties and opinions as to the effectiveness of the
approval process brought about by diverse perceptions of the roles and responsibilities
of the IRB/IECs.
i) A reflection of one
For the past three years I have had the privilege of managing the
Administrative Support Group for an IRB and the experience has been illuminating.
The work load has expanded to the extent that in this period the IRB has increased the
number of members and now meets at least once each week, instead of every other
week. The dedication and seriousness which the members bring to each task is
exemplary and often in marked contrast to that of the investigators who are asked to
respond to queries, provide explanations or make changes to their documents. The
concept of patient protection dominates each protocol evaluation and I have heard
discussions as to whether a placebo was ethically justified in one study while another
study was challenged because the absence of placebo might invalidate the study results
and therefore it was deemed unethical to enroll patients. As Sackett reminded us
(148) a poorly designed study is always unethical.
Perhaps the last word as to who should decide whether or not the use of
placebo in a particular study is ethical can be left to Hoffenberg (164) The whole point
about ethical decisions is the inherent difference of opinion. If there were total
agreement it would cease to be an ethical problem.' No doubt IRB members benefit
from continuing education as to their responsibilities but in my experience the IRB
review and evaluation of proposed studies to ensure patient protection is effective and
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much more attention needs to be directed towards educating the investigators about
their roles, responsibilities and performance.
c) Deception and Informed Consent
Critics who claim that the use of placebo always entails patient deception are
perhaps ignoring or misunderstanding the concept of Informed Consent. Or perhaps
they are confusing clinical trials with clinical practice wherein informed consent does
not exist even for invasive procedures such as phlebotomy or lumbar puncture,
because patient consent is assumed from the fact that the patient has voluntarily
consulted the physician for diagnosis and treatment. It is true that major procedures
such as surgery require written consent, but most times this is driven by the need for
legal protection of the hospital and surgeon rather than a genuine desire to inform the
patient.
The concept of Informed Consent is in recognition of and respect for patient
autonomy. It provides the opportunity for the patient to make a considered decision
as to whether or not he or she should participate in the study, based on a full
explanation of the study goals and procedures, the potential risks and benefits,
especially if the latter are more likely to accrue to society in general rather than the
patient in particular. In the United States the FDA have provided specific requirements
as to the information, protections and other treatment options that must be included in
the consent form (165). They also specify that the Principal Investigator must be the
person who obtains the consent, that this should usually be written but must always
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be witnessed (165, 166) and that the IRB must approve the proposed consent form
before it is used (152). The international requirements specified by the ICH are similar
to the FDA mandates (167). Interestingly, both groups allow waiving of consent
under specifically defined circumstances (Sections 50.23 and 4.8.15, respectively)
and this may have given rise to many of the subsequent problems. Some other
groups have weighed in with their own guidelines and laws all of which broadly
encompass the same scope of respect for the autonomy of the patient with voluntary
informed consent (168, 169, 170).
i) Do all investigators follow the rules?
Two authors have noted recently that there has been a substantial erosion in
public confidence in the medical profession and particularly in medical research, as a
result of some recent disclosures. For example, in the gene-therapy study at the
University of Pennsylvania in which a young man died, the consent form which he
signed did not disclose the fact of primate deaths after receipt of the gene-therapy
vector that he was to receive (171). The outgoing Head of the Department of Health
and Human Services has suggested that researchers may not be doing enough to
ensure that subjects fully understand the risks and benefits or may misinterpret the
nature of the trial to patients (172) and the Office for Protection from Research Risks
has found investigators downplay the risks of the study and enroll inappropriate
patients (171). It also seems that many investigators fail to mention the inclusion of a
placebo in the trial when informing patients about the trial (173).
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ii) Is informed consent always necessary in clinical trials?
Even Beecher had some doubts about this writing, 'Informed consent is the
goal towards which we strive. There may be a modest exception to this in
circumstances in which there is no discernible risk and where discussion with the
patient would vitiate any possibility of success ' (174). More modern authors
also find occasion when consent can be waived (175) and cast doubt on the claim that
informed consent provides protection against patient exploitation in research. They
made a well reasoned case but found little support for their views in the subsequent
correspondence sections of the journal. Still others claim that to provide full
information may be harmful to patients, or that it is inhumane to physicians and
patients to insist on full disclosure, and believe that clinical judgement should
determine the need for disclosure. Further, they propose that individual investigators
themselves should decide if formal consent is necessary in their trial (176, 177),
presumably on the principle that the fox can be trusted to guard the chicken coop.
Others espouse beneficent paternalism even further, suggesting that if the trial is
ethical and scientific (they don't explain who decides this) the issue of informed
consent need not always arise (178).
The possibility that full appreciation and knowledge of the trial may inhibit
patient recruitment has been suggested as a justification for avoiding informed consent
(175, 176, 179), and it has been suggested that telling patients they might receive
placebo reduces the effect of the active drug in the study (180). Withholding from
patients information that a placebo would be included in the study was discussed as
part of an extremely comprehensive review of placebo presented to the Medical Ethics
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Institute, but when Brody (181) said that not all patients expect the physician to tell
them the name of the prescribed drug and that a vague comment like 'this will make
you better' would often suffice, his remarks did not elicit any challenge, at least as far
as I could ascertain.
In my opinion none of these arguments have validity. As we have seen,
clinical trials are experiments, not an extension of patient care. By agreeing to
participate in a trial the patient is giving up the right to treatment which is specifically
tailored to the patient by the physician, relinquishing freedom of choice in many
aspects of treatment and subjugating personal beneficence for social good. For these
reasons I believe that the informed consent process, including the explanation of the
study, must be intense, stringent and scrupulously applied.
iii) How comprehensible is informed consent?
Beecher posed this question (149) and suggested that consent in a fully
informed sense may not be obtainable. Can we ever be sure that the patient has
completely understood the information provided and how can this be understanding be
assessed? Many physicians have difficulty in admitting to patients their uncertainty
which justifies the conduct of the study (182). More worrying still is a study showing
that only about one third of all patients believe that physicians explain things well
(183). These concerns have been addressed in the context of patient enrollment in a
study and how this affects the physician - patient relationship, possibly leading
patients to believe that the suggestion to take part in the study is actually a
recommendation that this is the best course of treatment for them (184).
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When patients talk to a physician they are usually anxious and concerned about
themselves or their relative so they do not always comprehend what the physician is
telling them, they misinterpret words and have difficulty separating the major from the
minor. It is easy to overestimate the degree of comprehension that patients and
relatives take from our medical information and instructions and I learned this lesson
when a House Surgeon, listening as the Chief attempted to explain to a patient's wife
the difference between possible and probable risks of the proposed surgical procedure.
Sensing that the subtle difference was not being grasped he pointed out of the
Infirmary window and said,
"Suppose I told you that the Moderator of the Church of Scotland and the Pope
were holding hands and dancing in the street. Now, you might agree that this
could be possible, but do you think that it would be probable?"
The lady considered the problem for a moment then replied
"I really couldna say doctor; ye ken, I'm no a Catholic."
iv) What should we do?
A recent report (185) has noted that problems with informed consent are
among the most frequent adverse findings recorded during audits and inspections of
clinical trials and in a recent survey 40% of the respondents, from the USA and
Europe, claimed that they had come across questionable informed consent practices
such as backdating documents.
Shalala (172) recommends increased training in bioethics for IRB members and
investigators. Others want to strengthen the IRB/IEC role (186) but do not explain
Burt/TITP 72
how the IRB/IEC is supposed to monitor each patient enrollment, while another group
has suggested how the Boards could conduct better reviews (187). Unfortunately, the
Boards are already overworked and any further increase in the workload might produce
an effect that is the opposite of that intended. It certainly does not help to restore
confidence and encourage participation in the IRB/IEC functions when law suits are
filed against the individual members (188) but perhaps these will have the benefit of
increasing awareness of the difficulties faced by the Boards.
A patient who has taken part in clinical trials (189) and a researcher who has
also been a patient in a study (190) recommend that input from potential patients
should be obtained at the design stage of a clinical trial. They also make a plea for
more education of the public so that there would be greater understanding of the need
for clinical trials, the rationale for the different designs and the relevance of trials to
'root out useless and harmful drugs and assess new ones'.
A report from the House of Lords suggests that physicians who wish to practice
Alternative Medicine should have proper training in the techniques they employ (191)
so why should the same standard not be applied to those who wish to undertake
clinical research? Education and training in the ethics, regulations and methodologies
of clinical trials for all their physicians who wish to be involved in clinical research is
now being introduced by a number of the Managed Care and University Hospitals in the
US, driven by the fiscal/legal pressure to safeguard the hospital and employees from
lawsuits.
We also must address the training of those who take part in the informed
consent process, so that they explain things clearly and establish a two way dialogue
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with the patients to ensure that they really do comprehend what they are being told.
What the physician says is not as important as what the patient hears and interprets.
Given these difficulties I can understand the critics who claim that placebo use
is unethical because the informed consent process offers no protections, but I think
that they are aiming at the wrong target. They should be concentrating on improving
the consent process, because the weaknesses in the process apply to all studies,
medical and surgical, and not exclusively to use of the placebo.
If, without these steps, critics of placebo continue to insist on full
comprehension by each potential participant, then soon we will be limited to enrolling
only medical or surgical colleagues! Perhaps this will help to increase understanding of
the placebo effect and quell some of the criticism, but as matters stand at present,
the critics' concerns about the adequacy of the informed consent process are absolutely
valid, even if their criticism of placebo is not.
d) Infringement of rights and codes of ethics
Critics usually like to claim that the use of a placebo denies the patient's rights
as laid down in the Hippocratic Oath, infringes the concepts of beneficence and
autonomy as defined in the Belmont Report and is prohibited by the Declaration of
Helsinki. These broad generalisations have elements of truth but once more they
apply to all forms of clinical research rather than to placebo in particular.
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i) The Hippocratic Oath
Familiar to all physicians from graduation, this is the first code of
medical ethics, originating in ancient Greece with Hippocrates, the Father of Medicine.
The biography in Encyclopaedia Britannica suggests that Hippocrates as a character
was possibly a combination of several physicians from the same period rather than a
single person, but no matter, the Oath remains as the accepted standard of physician
behaviour and ethics today. The original oath, of course, was written in Greek and
for an English translation I turned to the Encyclopaedia (192). The relevant sentences
seem to be that the physician 'will abstain from whatever is deleterious and
mischievous' and 'will strive always for the benefit of my patients'. Critics point out
that the use of a placebo is deleterious and mischievous, particularly if deception is
involved, and that substituting ineffective therapy for effective therapy is not a patient
benefit.
Another frequent criticism that is usually wrongly attributed to the
Hippocratic Oath claims that the use of a placebo contravenes the dictum of primum
non nocere 'First do no harm'. There is an echo here of the early Biblical translation
difficulties in that the original Greek oath was translated into Latin and thence to
English, but I could find no part of the English translation that matched primum non
nocere. Lasagna undertook a more thorough search (193) of different translations and
concluded that this admonition did not come from the Oath.
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ii) The Belmont Report
Although not invoked so often as the others by the critics of placebo,
this uniquely American code is a guide to the IRBs in their review of research projects,
informed consent and institutional compliance, and is neither aimed at individual
research projects nor does it address the place or role of placebo itself. The National
Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research was formed after the revelations of patient abuse described by Beecher (149,
174). Concerns also had been expressed over some behavioural studies, the
government sponsored Tuskegee Study and some radiation studies, so the
Commission was formed in 1974 by the National Research Act, met at the Smithsonian
Institution's Belmont Conference Center in 1976 and their report (194) was published in
the Federal Register in 1979. The length and complexity of the Commission's name
guaranteed that this would always be known as the Belmont Report!




Respect for persons incorporates the ethical dictates that individuals must be treated as
autonomous agents and that persons with diminished autonomy, for example the very
ill and the institutionalised, need especial protection by virtue of their being particularly
dependent and therefore may have a reduced capacity to give consent. Beneficence
implies first that no harm be done and second that possible benefits be maximised and
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risks minimised. Justice requires fairness in selection of research subjects so that
certain classes, ethnic minorities and welfare participants are not unduly represented
simply because they are easily available.
If these precepts are followed by the IRB/IECs then critics of placebo
use should have no case to argue.
iii) The Declaration of Helsinki
This has become the dominant code of ethics world wide and has
superceded the Hippocratic Oath as the code for medical research. Almost all critics of
the use of placebo complain that such use is a direct and unethical contravention of
Section II, Medical Research Combined with Professional Care, and specifically
disallowed by paragraph 3. The paragraph was added to the Declaration in 1975 and
reads: Tn any medical study, every patient - including those of a control group, if
any - should be assured of the best proven diagnostic and therapeutic method. This
does not exclude the use of inert placebo in studies where no proven diagnostic or
therapeutic method exists.'
According to Rothman and Michels (141) this statement 'effectively
proscribes the use of placebo as control when a "proven" therapeutic method exists.'
and in response to the flurry of Letters to the Editor that followed their article, these
authors state again 'As we noted, the requirement of placebo controls violates the
Declaration of Helsinki.' (195). Stephens (196) believes that placebo-controlled
studies should be the exception and are justified only in exceptional circumstances,
while Rothman (145) hopes that such studies will rapidly become obsolete. Michels
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has been quoted (146) as stating that placebo-controlled trials are unethical and
immoral while at another meeting the editor of the journal IRB, Bette Crigger,
commented that there is increasing polarity in the research community over the
placebo issue (197). So, what is this document that has come to dominate and give
rise to such bitter divisions in the pursuit of medical research?
In 1964, following the Nuremberg Trials that disclosed the extent of the
Nazi atrocities committed in the guise of research, the World Medical Association
(WMA) at their General Assembly meeting in Helsinki put forward recommendations
drafted only as guide to physicians all over the world (198). The authors
acknowledged that their recommendations would require modification and should be
constantly reviewed. This has occurred at the General Assembly meetings in Japan
1975, Italy 1983, Hong Kong 1989, and South Africa 1996. At none of these
meetings since the paragraph was added in 1975, was any change or addition
proposed for Section II, paragraph 3.
The 2000 General Assembly meeting was held in Edinburgh and the
delegates clearly took account of the advice that was submitted from various quarters
(199 - 204) before producing their fifth amendment to the Declaration ( 205). It was
clear that this was the most comprehensive revision since the inception of the code;
the framers made clearer reference to the IRB/IEC rights and obligations, and
strengthened the requirements for informed consent (206, 207, 208). The text
concerning placebo use was slightly expanded but left the intention almost unchanged:
The benefits, risks, burdens and effectiveness of a new method should be tested
against those of the best current prophylactic, diagnostic and therapeutic methods.
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This does not exclude the use of placebo, or no treatment, in studies where no proven
prophylactic, diagnostic or therapeutic method exists.' (208).
It is worth pointing out that from the beginning the WMA recognised
that their recommendations were not going to result in a global consensus.
Differences in ethical standards, variations in perception and medical interpretation,
availability of diagnostic techniques and treatment choices, differences in culture and
language were bound to produce differences of opinion. Not surprisingly several
countries have produced their own modifications applicable to their own requirements
and circumstances (209 - 211) to complement the Declaration.
I believe that those critics who insist that a strict interpretation of
paragraph 3 prohibits the use of placebo as unethical, are mistaken. After all, a strict
interpretation requires that every patient, including those of a control group, if any,
must receive the best proven therapeutic method. Thus a new drug cannot be
evaluated at all, because, by definition, it cannot be the best proven current
prophylactic, diagnostic and therapeutic method without comparison and proof, and
thus it is excluded by the demands of the code. So, strict interpretation rules out ALL
therapeutic research and precludes the evaluation of any new therapeutic agents or
methods. Fixed dose studies, which means almost all studies, are also excluded
because best therapy often requires dose titration for maximum effect.
Although I would like to claim that this argument is original and my own,
it isn't. It has been put forward by several authors, Collier (142), Stephens (196)
and Lasagna (199) to name only three that we have already discussed. Curiously,
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given the vehemence with which they defend their absolutist position, the critics of
placebo have offered no rebuttal to these three, at least none that I have been able to
find.
e) The Regulatory Agency makes me do it
On several occasions the critics of placebo have blamed the various regulatory
agencies, particularly the US Food and Drug Administration (FDA), for demanding
placebo-controlled studies for evaluating new drugs and regarding this design as the
gold standard (144, 145, 195, 212). Even Lancet, in an otherwise impassioned
defence of the FDA suggests that their acceptance of placebo-controlled evidence in
preference to an active comparator is a serious flaw (213). In my opinion these
statements suggest an inadequate reading of the Code of Federal Regulations and are
intended to obfuscate the issues so that the critics can portray the FDA as bureaucratic
and inflexible, forcing everyone to undertake unethical studies. Do the FDA and other
regulatory agencies in fact demand placebo use and is there coercive pressure applied?
The term "gold standard" was applied by the Editor of the New England Journal
of Medicine (214) to the clinical trial design in which systematic selection bias has been
reduced by the double blind presentation, random allocation of treatments and a
placebo control. The words "gold standard" do not appear in the Code of Federal
Regulations and it is an intellectual stretch to apply them only to the placebo
component of the required triad.
In the Code the FDA 'requirements and procedures for submission to and
review by the agency of applications to market a new drug.' are clearly stated (215).
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The relevant section for our consideration here is 314.126a which defines adequate and
well-controlled studies needed to 'provide the primary basis for determining whether
there is "substantial evidence" to support the claims for effectiveness for new drugs.'
The FDA suggest and discuss no less than five possible choices for the control:
Placebo concurrent control
Dose comparison concurrent control
No treatment concurrent control
Active treatment concurrent control
Historical control
The Guidelines published by the International Conference on Harmonisation (216) list
the same possible choices, but with reservations concerning the Historical control.
What is undoubtedly correct is that there is a need to include a placebo control
in studies where the response is either totally or mainly subjective, the classic example
being the evaluation of putative analgesics in patients with pain. As we have already
seen, in such circumstances there is potential for a large placebo effect and the only
way in which this can be discounted is by including a placebo control. As a member of
the Analgesiology and Headache Section of the American Society for Clinical
Pharmacology and Therapeutics I took part in several discussions between the
members and the FDA as guidelines for the evaluation of analgesics were prepared and
reviewed (217). Placebo control was discussed extensively and the recommendation is
that 'The study design should include a comparison of one or more dose levels of the
test drug with a placebo and, generally, with a standard analgesic.' The purpose of
the placebo is to provide validation of the downside assay sensitivity and if placebo is
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not used then some other method to verify assay sensitivity must be found to provide
substantial evidence of efficacy of the test drug.
Patients with rheumatoid arthritis have pain as one of their major symptoms
and the FDA guidelines for the evaluation of new anti-inflammatory drugs (218) also
address the use of placebo control. In trials to demonstrate superiority of the new
drug in patients with mild disease and who are taking say, an NSAID, the guidelines
recommend that a placebo control should be used but with all patients continuing to
take their NSAID therapy during the study. Patients who are responding poorly on
NSAIDs alone are usually not candidates for placebo-controlled studies.
Obviously the regulatory agencies see a need for placebo-controlled studies and
the various available study designs will be discussed in more detail in another section,
but I am not convinced that any of the written guidelines specify placebo use in every
study or that there is coercion or pressure to use placebo. However, there is pressure
to ensure that the studies are so designed that they are ethically and scientifically valid
and that the data are interpretable.
f) Denial of effective therapy
Critics who claim that inclusion of a placebo is unethical because it
denies effective therapy to the patients, in my opinion are making three specious
assumptions.
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i) Withdrawal of active treatment
Michels is quoted asking emotionally 'if the patient was your son or your
mother, would you withdraw active treatment for the sake of science?' (146). But is
her question valid? Although she implies that the son or mother was receiving a drug
which had pharmacological activity this may not have been an effective treatment or
even well tolerated by the patient. In other words, Michels has glossed over the
possibility that there might be a sound medical reason for withdrawing the active drug.
When a patient is receiving treatment for a disease which is responding
to this treatment, and the treatment is well tolerated, I can see no ethical justification
for withdrawing this treatment. Protocols that I have written insist that a patient who
is already receiving treatment for the relevant disease may be enrolled in the study only
if there is a sound, ethical, medical reason for withdrawing this treatment - say
because of unacceptable secondary effects of the drug. Withdrawing successful
treatment simply to enroll a patient in the study is to my mind unethical, and one can
imagine that the indignation stirred up by Michels' question probably dominated the
discussion and overlooked the illogicality of her question.
ii) Active drugs are always effective
The second specious assumption is that all active drugs, at all doses,
are effective treatments in all patients all the time. If life were that straightforward
then such a concept would simplify therapeutics, but unfortunately it isn't and it
doesn't!
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iii) Placebo is synonymous with no treatment
The third specious assumption equates placebo with no treatment and
indeed Rothman and Michels (141) and Hill (219) pose the question 'So what if the new
treatment is better than nothing?' in the clinical trial.
By definition an inert placebo is devoid of any inherent pharmacolgical
activity and if the critics were to claim denial of a specific therapeutic effect, for
example that placebo has no antibacterial action, then their assumption might become
more persuasive.
Objective responses:
Although we do not understand the mechanism by which they are
produced, objective responses to placebo have been documented. In a series of
experiments that have now become classics Wolf (220) was able to observe changes in
the gastric mucosa and gastric secretion in Tom, a patient who had a permanent
gastric fistula through the abdominal wall as a result of a gunshot wound. Wolf
recorded changes in gastric secretion and vascularity occurring in response to
emotional stimulus and showed that these could be blocked by placebo treatment.
Tom hated injections of any kind and an intramuscular injection of distilled water would
be followed by an increase in gastric blood flow, confirming that placebo effects on
end organs could be measured. Neostigmine given repeatedly induced hyperactive
gastric motility, abdominal cramps and diarrhoea as would be expected, but on other
days when the neostigmine was withheld Tom would experience the same gastric
effects in response to atropine, lactose tablets or distilled water. A modern review of
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studies describing the treatment of gastric ulcers (221) showed that after eight weeks
48 - 58% of patients treated with placebo were cured, whether or not they had also
taken antacids. Treatment of duodenal ulcers showed a cure after four weeks in 24 -
45% of patients who took placebo with antacids and in 29% of the patients who took
placebo without antacids.
In a 28 year old female patient with persistent hyperemesis, Wolf (220)
effected a cure by initial treatment with repeated doses of ipecac which produced
nausea and vomiting. Once she was conditioned he treated her with ipecac together
with a placebo which she was told would cure her, and it did. A recent review of
studies in patients after surgery (222) showed that 20 - 99% of those treated with
placebo did not have nausea or vomiting while other investigators (223, 224) reported
no vomiting after laparoscopy in 55 - 68% of patients treated with placebo.
In patients with angina pectoris, placebo treatment has improved
exercise tolerance, reduced consumption of nitroglycerin and been associated with
ECG changes (225). In studies performed to evaluate nicardipine similar findings were
reported in patients with angina (226) while patients with hypertension who received
placebo had a reduction in mean diastolic blood pressure although this was significantly
less than that seen in the patients who received the active drug (227, 228).
Placebo treatment has produced objective changes in diabetic patients
(229), changes in blood sugar, serum lipoproteins and white cell counts (230): in
patients with anxiety, injection of isotonic sodium chloride mimicked the response to
an injection of corticotrophin, increasing neutrophil counts and the uric acid/creatinine
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ratio, decreasing lymphocyte and eosinophil counts and changing serum levels of
potassium, sodium and 17-ketosteroids and blood lipids (94).
Subjective responses:
In his review of 15 published studies Beecher (94) found that 15 - 58%
of patients with pain reported relief after placebo treatment, and in his own studies
(231) showed that 53% of patients with severe post surgical pain obtained relief
following a single dose of placebo. Jellinek reported that 82 - 87% of patients with
headaches obtained relief from analgesics but found that 60% of patients being treated
with placebo also obtained comparable relief (232). A review of studies in patients
with anxiety suggest that 24 - 71% of patients treated with placebo show a beneficial
response (233).
Nocebo responses:
Given the objective and subjective responses described above it would
not be surprising to find that these carried over to mimic the adverse events seen with
active drugs. In a series of 109 Phase I, pharmacokinetic studies involving 1,228
healthy subjects (234), reports of headache, asthenia, drowsiness, nausea and
vomiting, abdominal pain, impaired concentration, dry mouth and sleep disorders
were made by 0.4 - 12.5% of the subjects. Beecher recorded (94) reports of dry
mouth, nausea, headache, the sensation of heaviness, impaired concentration,
drowsiness, warmth, relaxation, fatigue and sleep disorders from 9 - 50% of 1,082
patients with pain who received placebo in 15 studies. In patients with anxiety and
tension (235) there were three major adverse events recorded in patients who
received placebo. One reported weakness, palpitations and nausea, one reported
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epigastric pain, diarrhoea and developed angioneurotic oedema of the lips and the
third developed a diffuse rash, diagnosed by a dermatolgist as 'dermatitis
medicamentosa,' which cleared up when the patient stopped taking the lactose
placebo.
Placebo can induce protean objective and subjective effects and
responses which should not be ignored simply because we cannot yet provide a
scientific rationale to explain how they occur. With these well documented effects and
responses to placebo it seems hardly reasonable to claim that placebo is truly
synonymous with no treatment: Beecher (236) was more succinct when he wrote The
concept that placebos are inactive indicates considerable misunderstanding.' and it






MEDICAL RESEARCH AND THE ESSENTIAL
PLACEBO
So far the placebo has been considered only as a treatment and the arguments
for and against such use have been reviewed. Today there are very few, if any,
reasons to even consider using placebo as sole treatment but there are some genuine
questions in modern therapeutics that can best be answered by incorporation of a
placebo.
The line that separates medical practice from medical research is not
unremittingly straight but wanders from one side to the other, in a narrow and blurred
manner so that often it is not possible to be certain exactly on which side of the line
one is placed. This was recognised, with caveats, in the revision of the Declaration of
Helsinki (205); The physician may combine medical research with medical care, only
to the extent that the research is justified by its potential prophylactic, diagnostic or
therapeutic value.'
Like many foot soldiers in the history of warfare who played a significant and
major part in individual battles and then became anonymous and overlooked when the
leaders received the glory and the laurels of victory, the contribution of placebo is
often anonymous and overlooked and the essential role that it sometimes plays in
improving medical practice is ignored. As we have seen there are plenty of critics who
claim that placebo use in medical research is also unethical. In my opinion this
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absolutist view is not only untenable but also overly simplistic and if implemented
unthinkingly would add to the unanswered questions in modern therapeutics.
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VIII.SOLVING PROBLEMS IN MEDICAL PRACTICE
Placebo to the rescue
Keep watch also on the fault of the patient which often makes
them lie about taking of things prescribed.
Hippocrates, ca. 460 - 377 BC.
a) Missing doses
Patients do not always take their drugs as prescribed. The phenomenon of
missing doses is known as 'lack of compliance', and it seems that practitioners
overestimate their ability to recognise the frequency and ubiquity of this problem (237).
Modern drugs, unlike their predecessors so disdained by Holmes (54) and
whose lack of efficacy and therapeutic value was bemoaned by Sir Derrick Dunlop, are
so potent, powerful and effective that the latter referred to them picturesquely as the
Therapeutic Thunderbolts of Jove' (238). However, no matter how potent or
powerful, not even a modern drug can produce a therapeutic effect if it isn't taken and
a drug that is taken irregularly cannot produce its full therapeutic effect.
The reasons that patients miss doses range from simple forgetfulness,
resolution of symptoms being interpreted as ablation or cure of the disease, the
occurrence of adverse secondary effects, a difficult or inconvenient dosing schedule
which conflicts with work or social activities and, increasingly for older patients on a
fixed income, the desire to save money by skipping doses and prolonging the lifetime
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of the current prescription. Unfortunately, missing doses can have serious
consequences beyond the fact that the patient is not getting effective treatment.
i) The oral contraceptives
The successful extraction of diosgenin from the Mexican yam by the
chemists who founded Syntex Corporation, Drs. George Rosenkranz, Alex Zaffaroni,
Carl Djerrassi and Bert Bowers, enabled them to create the first synthetic progesterone
and oestrogen compounds, and led to their development of the first oral
contraceptives and topical steroids. To suppress ovulation successfully it is necessary
that the contraceptives be taken on a regular basis: in clinical trials of one current
product, Ortho-Cyclen, for example, 1,651 subjects were studied for 24,272 cycles.
During this time only 18 subjects became pregnant, most of these because they did
not take the drug consistently, as prescribed (239).
The necessity for good compliance with the dosing schedule became
even more critical in the 1970s when the 'mini' pill, with lower doses was introduced
and physicians needed an answer to the question "How many doses can I miss before
being at risk of becoming pregnant?" In the 1980s there were five clinical studies
including one by Edinburgh colleagues (240 - 242), which used the placebo
substitution design, in which placebo tablets were substituted at different times in the
cycle and for different duration, during and after which suppression of ovulation was
measured.
Clearly this is medical research but it meets the requirements spelled out
in the Declaration and it has direct applicability to everyday clinical practice and life in
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general. Physicians can answer patient concerns and provide advice based on good
science and the patient gets the information written in simplified lay language and
enclosed in the drug package (243). As a bonus there is the pack itself in which
placebo, the humble foot soldier plays a crucial role. As can be seen from the
photograph of the pack (Figure 5) blue tablets are to be taken for the first 21 days of
the cycle: these contain norgestimate and ethinyl estradiol, colouring agents and the
inert ingredients lactose, magnesium stearate and starch. For the next seven days
the woman takes only an inert green placebo, described in the package insert as made
up of colouring agents, lactose, magnesium stearate, cellulose and starch. Inclusion
of these placebo tablets has simplified the dosing sequence to one pill once daily
throughout each month which makes the schedule acceptable, convenient and more







ii) Drug holidays and forgiveness
Patients being treated for life long, chronic diseases do not always take
their treatment regularly or as prescribed, stopping or adjusting the dose and
frequency as they learn what best suits them. A large study in the United Kingdom
(244) found that almost half of the 37,643 hypertensive patients either changed or
discontinued their treatments within six months of starting. More recently, using
electronic monitoring devices placed in the bottle cap, (237, 245, 246) researchers
were able to confirm that lapses in compliance with antihypertensive drugs were
mirrored by an increase in blood pressure and concluded that up to half of all
"therapeutic failures" seen in hypertensive patients may simply be due to a lack of
compliance in taking the prescribed treatment. Another author (247) has suggested
that while 50 - 60% of hypertensive patients almost always comply with the
recommended treatment and 20 -40% usually comply, there remains a core of 5 -
10% who never comply.
A study of patients with ankylosing spondylitis showed that only 22% of
the patients complied strictly with the prescribed schedule (248) and in another study
of psychiatric outpatients doses were missed on 19% of the days while 48% of the
patients failed to take their medications at all (249). It might be assumed that doses
would be skipped predominantly over the weekends but Rudd has shown that most of
the skipped doses are errors of omission and occur randomly, not in a systematic
pattern (250). Using the electronic monitoring device Urquhart has shown that they
seem to occur approximately monthly in one patient in six and about three to four
times a year in a further one patient in six (245, 246). Drug Forgiveness, defined as
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the post dose duration of effect minus the prescribed interval between doses, provides
an indication of how long drug efficacy remains following the last dose. Again using
the placebo substitution design, a study compared two 13-blocking drugs in patients
with hypertension (251). Control of blood pressure was maintained for up to six hours
after atenolol was replaced by placebo and for up to 48 hours after betaxolol was
replaced by placebo.
Clearly betaxolol is a more "forgiving" drug and a patient who missed
one or two days of dosing would be at less risk of loss of blood pressure control than
would be a patient taking atenolol who also missed the same number of doses. This
information might be of considerable help to a physician planning to treat a patient with
a (3-blocking antihypertensive and would also enable the physician to recommend a
course of action if a dose should be missed.
iii) Rebound and first dose effects.
When doses are missed the control of disease which had been exerted
by the drug is no longer present and this release of control can lead to rebound effects
such as the vasoconstriction that follows withdrawal of p-blocking drugs. It may be
necessary with some drugs that treatment be started with an initial small dose, well
tolerated although probably not fully effective, and then the dose be gradually
increased to a level at which it is well tolerated and fully effective. After missing a few
doses it is usual for the patient to restart taking the drug at the same dose level as was
last taken and this may lead to the sudden appearance of those secondary
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pharmacological effects which were avoided by the initial careful upward dose titration,
the so called first dose effects.
It has been suggested (246) that the problems described above could be
identified early in the drug development program if the placebo substitution design
were to be used more frequently and that it should be used also to extend monitoring
of patients beyond the end of study treatment and into the post treatment period to
ascertain the risks of rebound and breakthrough phenomena. With informed consent
there would be no deception, only the date of the change from active to placebo being
in doubt. Such studies would provide useful information to the practitioner intending
to prescribe the new drug, an explanation of the possible consequence of missing
doses and how this should be corrected.
iv) Single patient (N of 1) studies
Another role in which placebo has contributed to medical practice by improving
the therapeutic efficacy of drugs has been described recently (252). Although
Evidence-Based Medicine relies on the results from double blind, randomised,
controlled studies not all patients in such studies respond optimally, equally, or even
at all. When a new drug becomes available for widespread clinical use it is likely that
some patients will fail to respond or will report the appearance of secondary adverse
events. If the results of the double blind, randomised, controlled studies are to be
extrapolated to clinical practice then the single patient, or N of 1, study becomes
indispensable (253).
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This again employs the double blind, cross over, randomised design, but with
placebo substituted for the less than active, or suspect drug, which may be restored
later or replaced by another with similar activity but perhaps a different
pharmacokinetic profile. It is necessary to identify a target response for each patient,
say a sign or symptom which is particularly troublesome and such that would be
expected to respond rapidly when the stimulus is removed (dechallenge) and to return
equally rapidly if the stimulus is reintroduced (rechallenge). The technique may
require multiple active drug - placebo substitutions to be completely successful (254)
and experience over two and three years has been described (255, 256). The
technique is feasible, it increases the likelihood that that the prescribed treatment is
actually the best for that patient and helps to increase the physician's confidence if
there had been any initial doubt about the proposed treatment.
Although the single patient study is a formal clinical trial most of the usual
ethical issues do not arise because the objective is to identify the best treatment for a
specific patient and no other patients are involved. However, as with all trials,
informed consent is required from the patient who is free to withdraw from the exercise
at any time, and the same issues of confidentially apply to this design as they do to
any other trial.
An Editorial in Lancet (257) has described the single patient trial as an
innovation which, if widely used could be a powerful tool for physician and patient
education. Thus, it is difficult to understand why the concept has not been more
widely used, particularly as one author has drawn attention to the biases inherent in
open evaluations, namely the natural history of disease, placebo effects and the
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expectations of the patient and physician (258). Others have asked for research into
the reasons for this lack of acceptance of the technique (259). The Lancet Editorial
commented that even in 1986 'placebos are in everyday use.' but at least one
practitioner has called for the abandonment of placebo (260) on the grounds that
placebo effects 'cannot be clearly distinguished from specific treatments or therapeutic
skills.' Perhaps this concept requires more vociferous support and clarification of the
role and utility of placebo.
In these examples it is obvious that placebo is being used as a research tool to
answer specific questions and obtain information that is directly applicable to medical
practice, improving the effectiveness of treatment and enabling the practitioner to
respond to patient queries and concerns. This crossing of the line between practice
and research is an early indication of the essential role played by placebo in what might
be called practical medical research. The overall benefits are increased physician and
patient understanding, possibly better therapeutic efficacy as a result of better
compliance and almost certainly greater patient safety. Not an insignificant
achievement for a scorned tool.
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IX. CLINICAL TRIALS AND THE PLACEBO
In their haste to condemn placebo in all its forms the absolutist critics do not
challenge the need for the evaluation of new drugs to be carried out in anything other
than a rigorous, unbiased and scientific manner, but they fail to realise that their
position mitigates against exactly the requirements they espouse. To appreciate how
this occurs let us briefly review the steps in a clinical development programme for a
new drug and the most common study designs that are used at each step, to see how
placebo plays a major role in such development.
a) The clinical development programme
Traditionally this has been divided into four phases, but there is considerable
overlap of the lines of separation which are neither rigid nor fixed.
i) Phase I, clinical pharmacology
This is the first administration to humans, intended to assess tolerance,
define the pharmacokinetic/pharmacodynamic (PK/PD) profile, identify the metabolic
pathways and the excretion pattern in healthy volunteers. These studies usually start
with a single, low dose and progress with dose escalation and multiple dosing and
typically involve less than 100 subjects. The data from these studies are immediately
relevant in planning the starting doses, frequency of dosing and steps for increasing
the dose in the next phase.
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ii) Phase II, therapeutic exploratory
Patients with the relevant disease but free from other, concomitant
disease or medications, are involved to establish the 'no-effect' dose, and explore
dose-response relationships. Usually of fairly short duration with surrogate or
pharmacological endpoints in addition to clinical measurements, these studies provide
proof of concept by establishing that the new drug has some efficacy, and provide
guidance for study designs in the next phase. Usually up to 500 patients may be
involved.
iii) Phase III, therapeutic confirmatory
Again involving patients with the relevant disease and free from
concomitant diseases and medications, these studies involve 2000 - 3000 patients and
are intended to confirm efficacy, refine the dose-response relationships and assess
safety. Involving larger numbers of patients than the previous phases these studies
are all double blind with random allocation of treatment and they form the majority of
the 'adequate and well controlled' studies required by the FDA and other regulatory
agencies.
iv) Phase IV, therapeutic use
Conducted after the new drug application has been filed and continued
long after the drug is marketed these studies involve patients with the relevant disease.
The study design still involves the double blind and random allocation of treatment but
the criteria for inclusion and exclusion are substantially relaxed so that patients with
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underlying diseases or taking concomitant medications can be enrolled. By this phase
the most effective, well tolerated dose will have been established and the duration of
these studies is considerably longer than in phase II or III. The object is expansion of
the safety information on the drug, particularly identifying the less common secondary
adverse events, and to assess comparative efficacy and additional endpoints.
b) Study designs
The same basic study design is used in phases II - IV, namely a comparison
between the new drug and the comparator(s), either placebo and/or active drug(s),
presented as identical in appearance to maintain the double blind, and allocated
according to a random code. The difference is whether groups of patients are
compared or each patient in the study receives each of the drugs.
i) The between patient design
This is the most widely used design and compares groups of patients,
one group who receive the new drug and the other(s) who receive the comparator
drug(s). Although it is most usual to have two groups it is not unknown to have both
a placebo and an active comparator group or even a 'no treatment' group. It is also
possible to compare two or three different doses of the same drug using this design.
ii) The cross over, or within patient design
With this design each patient in the study receives both, or all, the
study treatments allocated in random order. If three or more drugs are being
compared the allocation is usually balanced as a Latin Square to ensure that all possible
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order combinations are evaluated. At first glance this design would seem to offer the
most advantages by having the drugs evaluated in the same patient but the design is
unsuitable for any study in which the first period of treatment cures the disease and is
really only suitable for evaluating drugs to treat chronic diseases. Other drawbacks
include the occurrence of unacceptable adverse effects during the first treatment period
which lead the patient to withdraw before the second period and the difficulty of
exactly matching the presentations of the drugs being compared so that the patient
cannot identify the switch by a difference in shape, colour or taste. It was this latter
difficulty which led Sir Austin Bradford Hill, widely accepted as the father of the
modern clinical trial, to publish the following anecdote as a brief caveat on "that most
sacred cow, the prospective double blind randomised controlled trial." (261).
"Doctor," said the young lady patient, "Why have you changed my pills?"
"What makes you think I have?" was the cautious reply.
"Well last week when I threw them down the loo they floated, this week they
sink."
c) Several roles for placebo
Within these two basic designs there are several reasons and roles for placebo,
i) Matching the new drug
In the early phase studies most new drugs are presented in the simplest
formulation, in a capsule for oral consumption. This is unlikely to be the final
formulation selected for marketing but it recognises that the easiest comparator to
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produce is an inert placebo which can be formulated in a similar way and presented as
identical matching capsules. If capsules are unavailable or unacceptable, say for
reasons of stability, then tablets, with matching placebo tablets, are almost as
straightforward to produce.
ii) Placebo and the double dummy
When there is no possibility of the new drug and the desired comparator
being presented in identical appearance, for example when one is a solution for
injection and the other a tablet or capsule, the double blind can be maintained by the
double dummy technique. With this technique two placebos are used, one to match
the injection and one to match the oral product, so that each patient receives both
formulations, one active and one placebo. There is a disadvantage to this in that
each patient is required to receive 'double medication' which some patients may find
difficult to accept, and it also creates potential for non compliance or confusion as to
which dose is to be taken.
iii) Starting from the same point
Whenever two or more objects are to be compared it is important that
the comparison should start from the same point and contain the same evaluations.
With an acute intervention, say the assessment of post surgical pain, there is
obviously no problem, all the patients start after the surgery, but with chronic
diseases, such as hypertension or rheumatoid arthritis, patients may be at different
disease stages and even have received a variety of different treatments before entering
the study. For these reasons it is common to use a placebo 'run in' period during
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which any active treatment that the patient may have been receiving can be washed
out. This run in period also provides an opportunity to check that the patients do not
have pre-existing biochemical or haematological abnormalities and that the inclusion
and exclusion criteria are met. Once the disease has 'flared' to the defined level for
starting study treatment the placebo is withdrawn and the patient receives the assigned
study drug, which in appearance is identical to the placebo, so that the patient is
unaware of the start of active treatment.
It will be apparent that when the cross over design is used these caveats
apply not only at the start of the first period of treatment but also must be applied
before the start of the second period, to ensure that the disease state is at the same
level at the start of both treatments and that there are no carry over effects from the
first drug which might be attributed to the second drug. Without this second run in
period the study is invalid, and therefore by definition it is unethical. The crossover
design appears beguilingly simple but it was incorrectly used so often that in the late
1970s the FDA announced that they would not accept data from cross over studies in
the new drug submissions. Fortunately they have since modified their stance and will
accept this design provided that the study has been conducted correctly.
The run in period has been criticised as incompatible with informed
consent (262) on the grounds that fully informed consent and placebo go together
only where the treatment allocation is randomised. I disagree because when the
concept of the study is being discussed with the patient, the reason for the run in
period and fact that the time of the switch from placebo to active drug will not be
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apparent, can be explained. There should be no deception involved and the risk to
the patient should be minimal.
Brief withdrawal of active treatment in a study, provided that there is no
subsequent threat of morbidity or mortality, is no different from that often used in
practice for patients with hypertension, depression, anxiety, insomnia, congestive
heart failure or epilepsy, to assess whether or not the patient still needs it (199). A
recent systematic review of short term randomised, placebo-controlled trials in patients
with hypertension (263) found no difference in the incidence of those secondary
effects usually associated with untreated hypertension, death, stroke, myocardial
infarction and congestive heart failure, between patients treated with placebo and
those treated with active therapy. The authors acknowledge that these studies
included only patients with mild or moderate hypertension and the duration of exposure
to placebo was limited. In addition, because they were enrolled in a study, all
patients were closely monitored, probably considerably more closely than would have
occurred in routine practice, and this may also have contributed to the absence of
serious adverse events.
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X. PLACEBO AS A COMPARATOR IN CLINICAL TRIALS
So far we have reviewed the various reasons and roles for placebo as they
affect the design features of clinical trials, but this is not the use that upsets the critics
and leads them to disparage the studies. Their criticisms concern the use of placebo
as a comparator treatment in the clinical trial which, as we have seen, they deem
unethical and increasingly unnecessary (144 - 147). To consider and rebut these
criticisms it is probably best to look at studies as they are performed in Phases I - IV
and to consider with specific examples, including my own involvement and experience,
studies of different disease states.
At the outset it is worth recalling that even the most ardent opponents of
placebo insist that all drugs must be evaluated and compared in the most scientifically
rigorous manner compatible with patient safety, for only then can the results truly
identify the best possible treatment.
a) Phase I studies
These early studies generally represent the first human exposure to the new
drug and their purpose is to identify the PK/PD pattern. The subjects in these studies
are all healthy volunteers free from underlying disease, medications or drugs of abuse,
traditionally in the 20 -40 years age range and predominantly male, although this
latter is changing. As would be expected the informed consent process is detailed and
lengthy so that the subjects are fully cognisant of the procedures and the potential
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risks. It is common for the subjects to be confined to a residential facility where
resuscitation equipment is available and where they can be intensively and carefully
monitored throughout.
i) Pentazocine
At the start of my involvement in the pentazocine programme Professor
Beckett and I designed a series of studies to identify and compare the PK
characteristics of the drug given by different routes, intravenous and intramuscular
injection, oral solution, tablets and suppository (264). Four subjects took all doses
and a physician colleague and I were not only subjects in the study but also
administered the injections and collected all the samples of blood, urine and faeces.
ii) Benoxaprofen
This study was the first administration of the drug to humans, and
another medical colleague and I, although not participating as subjects on this
occasion, were available to monitor the subjects throughout the study (265). Once
again we were concerned only with identifying the PK pattern following single and
multiple oral doses, in fasting and fed subjects and also using oral formulations with
different particle size.
iii) Cinoxacin
This PK study (266) involved patients about to undergo transurethral
resection of the prostate who agreed to take four doses of cinoxacin in the 24 hours
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before surgery. At the time of this study we were well into the development
programme for cinoxacin and several hundred patients had taken it as treatment for
urinary tract infection. Because the patients scheduled for surgery did not have a
urinary tract infection at the time of the study and there was no reason to give the
drug beyond our need to measure plasma and prostate tissue levels, it was critical to
ensure that the informed consent process was unimpeachable. The surgeon and I
discussed the study with the patients, separately and on two different occasions,
before enrolling them and again before the first dose of cinoxacin was taken.
iv) A role for placebo?
Many of the early Phase I studies are designed so that a few of the
subjects actually receive placebo, while the majority get the drug being studied. One,
and perhaps the most obvious, reason for including placebo involves adverse events
and has already been alluded to (234). The potential for clinical trials to generate
placebo effects is much greater than that in routine medical practice so there is a need
to separate those adverse events reported during the initial human administration of
the new drug from the non specific placebo responses. When the subjects are confined
in a dedicated facility there is always the risk that some will become conditioned and
report adverse events that they have witnessed or discussed with other subjects.
The other reasons are more concerned with maintaining the integrity of
the study. It is not unknown for subjects to exchange doses of their drugs, (this
becomes difficult though not impossible, when the drug is given parenterally) and the
identification of the drug in the blood or urine of a subject who was thought to be on
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placebo indicates either drug swapping, a breakdown in the drug packaging and
allocation system or deliberate fraud on the part of one or more of the study personnel.
In my studies described above there was no placebo because in each
study I was working with a trusted colleague, I was present myself on each occasion
and personally witnessed the drug administration or taking thereof. Except for
benoxaprofen there was already considerable available data on adverse events
reported in clinical trials so we deemed that requirement for placebo control was
minimal.
v) Placebo isn't required for every study
There are also PD study designs where there is absolutely no
requirement for placebo. Pentazocine is a benzomorphan analgesic that possesses
both agonist and weak opioid antagonist properties. A single analgesic dose given
intravenously produced respiratory depression but we wondered if there was ceiling
effect or whether subsequent doses would produce cumulative depression as seen with
the morphine derivatives. With some of my former anaesthetic colleagues a study was
designed to investigate this question in a population of patients undergoing surgery
(267). The results showed a difference between pentazocine and pethidine with no
cumulative respiratory depression following a second dose of pentazocine. As all the
patients were asleep and all the measurements were objective there could be no
placebo response to be evaluated and therefore no reason to include a placebo in this
study.
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b) Phase II studies
As a general rule these studies are designed to show proof of concept, that the
drug has at least some activity even if the initial dose, chosen on the basis of PK data,
is not the optimum. With our understanding of the various components that make up
the placebo response it is to be expected that in any study several participants will
report improvement with the new drug, even if it is used at a 'no effect' dose. To
compare a less than fully effective dose with an effective dose of a marketed
comparator will inevitably lead to the conclusion that the new drug is ineffective. To
compare it to no treatment may be unethical and this design introduces bias because
the two treatments cannot be double blind. Provided that the patient's health is not
put at risk by the short term withdrawal of specific treatment the only logical
comparator in Phase II studies is the inert placebo.
Each new drug with which I have been involved has been evaluated for proof of
concept in initial studies with placebo comparators. Subsequently we identified the no
effect dose, the minimum effective dose and the dose response relationship. To
support my contention that placebo is essential, I have chosen three studies of
marketed drugs, in which I was involved, that required of proof of concept because
we were evaluating different uses or formulations of the drug.
i) Oral versus parenteral administration
In the late 1970s and early 1980s there was a surge in the growth of
outpatient day care surgery for minor operations, with patients returning home in the
evening of the day of surgery. At that time post surgical analgesia was usually
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provided by intramuscular (IM) injection of morphine or other opioid, but in many
instances the patients remained drowsy, with nausea or vomiting, when it was time to
return home. I wondered whether or not an oral analgesic could provide equivalent
and acceptable analgesia, so I designed a single dose comparison of fenoprofen,
morphine and placebo to evaluate proof of concept (268). As can be seen in Figure 6,
IM injection of morphine provided the most rapid relief of pain, significantly better than
placebo at all assessments. After two hours, oral fenoprofen was significantly more
effective than placebo though less effective than morphine, but over the next four
hours both fenoprofen and morphine remained significantly better than placebo and not
significantly different from each other. The percentage of patients who requested
rescue analgesics because of lack of efficacy of the study drug was 80% of those who
received placebo, 37% of those who received fenoprofen and 23% of those who
received morphine, showing that even a drug with specific activity is not effective in all
patients all the time.
These results confirmed the proof of concept that an oral analgesic could
be a practical and successful alternative to parenteral opioids for outpatient day care
surgery even if the doses in this study might have been too low for maximum efficacy.
That the statistically equivalent efficacy of oral fenoprofen and IM morphine was
genuine and not the result of a Type II error —wherein failure to reject the null
hypothesis occurred because the methods of assessment lacked sufficient downside




Figure. Mean pain intensity scores for patients with initial mod¬
erate pain. 'Significantly different (p < 0.05) from placebo.
fSignificantly different (p < 0.05) from morphine and placebo.
Figure 6
Reproduced from reference 268
ii) Pre-emptive analgesia in outpatient surgery
The staff at infertility clinics use hysterosalpingography (HSG) as one of
their diagnostic techniques. When I was an anaesthetist in the Royal Infirmary HSG
was performed under general anaesthesia, but modern fiscal pressures and work load
have made this less acceptable. The procedure produces excruciating pain at the
moment of attachment of the tenaculum and instillation of the dye, even when the
patient is encouraged to cough hard at the moment of attachment, but fortunately the
pain dissipates rapidly, within 15 minutes or less. Rather than having to provide
intravenous analgesia we wondered if an oral analgesic, taken approximately two
hours before the patient came to the clinic, might obtund, or at least reduce the pain,
so a small proof of concept study was designed to compare fenoprofen, aspirin and
placebo (269).
The results showed that of the fenoprofen treated patients 30% (5/15)
remained completely pain free at all times in the study, significantly more than the 7%
(1/15) of the aspirin treated patients and none of the placebo treated patients. By 15
minutes there were 13/15, 10/15 and 9/14 patients free of pain, respectively in each
group, and all patients were pain free by 45 minutes. Again, proof of concept was
confirmed although it seemed likely that larger doses and an adjustment in timing of
ingestion might make the oral analgesics more effective in even more patients. That
the statistical superiority of fenoprofen was genuine was confirmed by the significant
difference from placebo, inclusion of which also allowed an understanding of the
natural course of the induced pain.
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iii) Onset of analgesia
The anti inflammatory analgesic naproxen has been available world wide
for approximately 30 years and although it remains one of the better tolerated of this
class of drugs (270) a reformulation using the Intestinal Protective Drug Absorption
System® (IPDAS) not only provided even less gastro intestinal upset but also enabled
the drug to be taken only once daily (271). The sodium salt of naproxen is rapidly
absorbed after oral ingestion and is widely used as an analgesic so we were interested
to see if the IPDAS formulation, from which 30% of the dose is rapidly released and
the remaining 70% has delayed release, would be as effective as the conventional
formulation.
In a double blind, analgesic study using the third molar extraction dental
pain model (272) patients with pain of moderate intensity received either 500mg or
lOOOmg of naproxen in the IPDAS® formulation, naproxen conventional formulation
500mg, codeine 30mg or placebo, allocated at random. In the three groups who
received one of the naproxen formulations 70 - 73% reported onset of pain relief
within 30 minutes, compared with only 35% and 45% of those who received codeine
or placebo, respectively. PK analysis showed that by this time approximately 35% of
the drug had been absorbed from the IPDAS formulation. These results confirmed
proof of concept, namely that the new formulation was still a rapidly acting, effective
analgesic.
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XI. SOME CONSIDERATIONS FOR PHASE III AND IV
STUDIES
Phase III studies provide the bulk of the clinical data on which a new drug
submission is based, usually involving approximately 2,000 - 3,000 patients, most of
whom are treated as outpatients. Obviously the intense monitoring that is available
for phase I and II studies cannot be available in phase III but nevertheless the
regulatory authorities require scientific rigor and a study design that permits collection
of accurate and complete data so that the interpretations and conclusions that are
drawn are scientifically valid and can stand scrutiny.
Phase IV studies, starting after the filing of a new drug submission and
continuing throughout the life of the drug, move a little closer to resembling day to
day practice by loosening many of the inclusion and exclusion restrictions, reducing the
number and frequency of measurements and visits to the investigator. Nevertheless,
phase III and IV studies are still experiments and should be regarded as such when
being explained to patients who might enroll. Unlike the earlier phase studies these
later studies bring ethical considerations of their own in matters of equipoise,
uncertainty, superiority and equivalence studies and the presence or lack of assay
sensitivity and internal controls.
a) Equipoise and uncertainty
Given that it is the primary duty of all physicians unfailingly to promote the
welfare of their patients, the question arises, under what circumstances may a
physician ethically offer and suggest to the patient enrollment in a clinical trial? In the
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United States it is the principle of equipoise, meaning that there must be collective
uncertainty and doubt among the general medical community as to the best treatment,
before participation in the trial can ethically be offered (273). Rothman (145) notes
that without equipoise any therapeutic study is unethical. Recent examples of such
collective uncertainty include the debates over the treatment of breast cancer and
prostate cancer, lumpectomy or radical mastectomy, irradiation or radical
prostatectomy?
The principle of uncertainty, on the other hand, is widely endorsed in the
United Kingdom, where substantial uncertainty on the part of the individual
practitioner as to which trial treatments would be most appropriate for the particular
patient, is deemed sufficient to make offering the study completely ethical (274).
Another suggestion is that there must be uncertainty not only on the part of the
practitioner but also on the part of all the study participants, and if the answer is
already known then there is no need for the study at all (275).
Regardless which of these principles the practitioner prefers, there is the moral
imperative that the study design must meet all the previously discussed requirements
of scientific rigor, otherwise the study itself becomes unethical. The information for
the patient must make it clear that there is genuine uncertainty as to the best
treatment and so long as there is genuine uncertainty as to the best treatment, then
patients are not being asked to subjugate their autonomy for the good of others (276).
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b) Trials to show superiority
In clinical trials of new drugs efficacy is most convincingly shown by a dose
response relationship or superiority to a placebo or active comparator. A well designed
trial that shows clear superiority of one treatment over another offers the strongest
evidence of effectiveness and no other information is required to support this
conclusion (277), the study report will be accepted for publication somewhere and the
sponsor's marketing department will be ecstatic. In a patient with serious disease or
where there is risk that the patient's condition may deteriorate rapidly in the absence of
specific treatment, or when previous studies have identified a specific, effective
therapy, then placebo use is almost always unethical (278, 279).
It is worth noting, as a caveat, that the US Code of Federal Regulations (215),
in paragraph 314.126 defines the need for 'Adequate and well-controlled studied
(emphasis added) which is commonly interpreted as meaning that the FDA require at
least two such studies to be included in the new drug application (144). Presumably
this acknowledges the observation of the gambler Nathan Detroit in 'Guys and Dolls',
that once could be happenstance, twice is coincidence, but the third time is
deliberate.
c) Trials to show equivalence or noninferiority
Strictly speaking these are two separate concepts but in practice they tend to be
synonymous. Equivalence is generally limited to studies that assess bioequivalence,
where different formulations or routes of administration are compared, and the term
noninferiority is usually confined to clinical comparisons.
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In noninferiority studies the hypothesis to be tested is that one drug is superior
to the other, that is the opposite of superiority studies in which the more usual null
hypothesis postulates no difference between the treatments being compared.
Noninferiority studies seem easy to design but often there is not a clear understanding
of the principles behind the design so the studies fail to achieve their objective.
Frequently these studies have insufficient patients in the treatment groups and contain
design biases that may permit inappropriate conclusions to be drawn (279). Unlike
superiority trials in which the sample size is calculated on the basis of the expected
difference between the treatment groups, in noninferiority studies there is no expected
difference, hence difficulty in calculating the sample size. When the study is
completed the results may indeed show no difference between the treatment groups,
but were the treatments equally effective or equally ineffective?
d) Type I and Type II errors in data interpretation
In evaluating the results from clinical trials there are two potential errors. The
Type I error, in which the null hypothesis is actually true but is rejected (one treatment
is declared better than the other although in fact both are the same) and the Type II
error in which the null hypothesis is actually false but is not rejected (the treatments
are actually different but they are declared to be the same). Type II errors are
common in studies that lack assay sensitivity and in this case it is well to remember
that absence of evidence of a difference should not be construed as evidence of
absence of a difference (280).
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e) The perceived placebo effects
Earlier we considered the components of the placebo effect in practice. To
these components in a clinical trial setting must be added responses that are often
mistaken for placebo effects, but are more accurately described as perceived placebo
effects (281). It might be supposed that this is purely a semantic argument but as the
authors point out, the true placebo effect is highly variable and depends on a number
of factors that are as yet not fully understood. Therefore it is important to distinguish
the true placebo effects from perceived placebo effects that are reported in a clinical
trial, and the best way to achieve this distinction, according to the authors, is by the
inclusion of an untreated control group in addition to a placebo group. Exactly what
these perceived placebo effects may be is discussed below.
i) The Hawthorne Effect
This intriguing effect was first observed in studies at the Western Electric
Company plant located at Hawthorne, IL. Workers, manufacturing and checking
equipment for the Bell Telephone Company, were assessed to see if their efficiency
varied as a result of differences in available illumination. The answers seemed clear,
increased illumination led to increased efficiency, although several workers praised the
increased illumination when in fact it had not been altered, and other factors were also
identified which confused this simple interpretation (282). First, it was found that
when the workers knew that they were being observed their actions and work patterns
changed compared with when they were unaware of being observed. Secondly, they
were so called piece workers and their earnings depended on how much work was
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accomplished. When given feedback at the end of each day as to their output,
workers increased this the next day so that they would earn more. This is known as
the consequence of responding.
Thus the Hawthorne effect in experimental research is the unwanted
effect of being in the experiment itself, which leads to changes in behaviour patterns,
particularly apparent when the participants know that they are being observed or when
they are rewarded for their performance. A second study, assessing the performance
of Emergency Medical Technicians in ambulances, found the same effects, with the
participants' response depending on the perceived demand for service (283).
ii) The patients
Patients who agree to take part in a study are motivated by a desire to
succeed, perhaps because they have a chronic disease and grasp any potential
improvement. The sudden attention paid to them, the measurements and study
requirements and having more people interested in them than is usual in their routine
treatment, creates a powerful Hawthorne effect. For example, patients with
rheumatoid arthritis frequently show improvement in the first two or three weeks of a
study. Some patients, stimulated by the study and the interest shown in them may
add interventions of their own, particularly hypertensive patients who decide to reduce
their salt intake or lose weight. In some studies where compensation is offered to
participants, with more money being 'earned' if patients complete the study as per the
protocol, there is an obvious consequence of responding.
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iii) Regression to the mean
Patients enter the study when their disease is active or has flared,
either because of natural fluctuation, their existing treatment no longer works or is no
longer tolerated so they stopped it anyway or as a result of withdrawal of active drug
during the run in period of the study. For whatever reason, the study variables
measured at the start (baseline) are likely to be at the high end of a scale so
knowledge of the natural fluctuation in the disease state would suggest that
improvement will follow.
iv) Good compliance
As Urquhart has demonstrated in clinical trials (245, 246) compliance
with the treatment schedule is generally excellent for the first week or two, acceptable
in the third week and then deteriorates. Any Flawthorne induced change in behaviour
which leads to an alteration in the pattern of compliance will introduce unconscious bias
into the study and either exaggerate or diminish the response to the study drug so the
inclusion of a placebo may be necessary for the valid interpretation of the results.
v) Investigator's enthusiasm
Just as the practitioner generates an inherent placebo response, so
does the investigator who has his or her own motivation to conduct the study and see
it succeed. Payment to the investigator who participates is always a powerful
motivating influence, although this is often not disclosed to the patient.
Enthusiastically talking up the new treatment, describing the study and potential risks
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and benefits, encouraging the patient to take part because of genuine uncertainty as
to the best treatment, stressing the importance of adherence to the protocol and the
treatment schedule, all convey a sense of excitement and commitment for the patient.
Add a desire to provide the result that seems to be expected to support the
investigator, and bias becomes unavoidable.
vi) Passage of time
In studies of chronic disease, patients change as the study progresses.
One of the best documented changes is the acclimatisation seen in newly diagnosed
hypertensive patients who are susceptible to the 'white coat effect' and in whom the
early hypertension subsides as they become familiar with the staff and practice
procedures. This problem is so prevalent that a newspaper advertisement has drawn
attention to it (Figure 7) and home measurement of blood pressure is now
recommended to distinguish between pathological, sustained hypertension, and the
white coat version (284).
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By John J. O'Hara, Jr., MD
Cardiologist




If I've heard one
patient say that.
I've heard 100.
Or how about the
popular "That's
normal for me?" As a member of
the cardiology team at the Main
Line Health Heart Center. I can
safely say that there is no such
thing as "normal for me." Blood
pressure guidelines, as defined by
the Joint National Commission on
Hypertension, are crystal clear:
Optimal blood pressure is 120 (sys¬
tolic) over 80 (diastolic), normal is
less than 130 over less than 85,
high normal is 130-139 over 85-89
and needs to be watched carefully.
A blood pressure reading equal to
or greater than 140 over 90 is con¬
sidered high. With undetected,
uncontrolled hypertension the first
step to increased risk of stroke,
heart attack, heart failure and kidney
failure, knowing your blood pres¬
sure couldn't be more important.
It is true that some people expe¬
rience what is called "white-coat
hypertension." In other words, their
pressure spikes when they are in
their doctor's office. A simple plan
can reveal their actual blood pres¬
sure. First, buy a home blood pres¬
sure cuff. Second, lake and record
multiple readings at different times
of the day. Finally, bring that
record, along with your blood pres¬
sure cuff, in to see your doctor.
Your blood pressure will be taken
both on your home cuff and the one
in the office, to see if they corre¬
late. That is the only way "white-
coat hypertension" can be eliminat¬
ed as a factor, allowing us to focus
on what your true blood pressure
reading is.
When I started practicing medi¬
cine 25 years ago. we had three
drugs available to treat hyperten¬
sion. Today, numerous drugs are
available, administered alone or in
combination, to safely control high
blood pressure with minimal side
effects - even for pregnant mothers.
In America, some 5 million
Americans live with hypertension,
with 31.6 percent of those people
unaware of the problem. Since high
blood pressure is easily detected
and is usually controllable through
a combination of diet, exercise and
therapeutic drugs, the more you
know about your blood pressure,
the better.
V-
Main Line Health Heart Center is one of the largest, most experienced
and comprehensive heart centers in the country. For more information,
call 1-866'CALL MLH. or visit us online at www.mainlinehealth.org.
Dr. 0 Hara, a cardiologist with
the Main Line Health Heart
Center, has practiced in the
Paoli area for 20 years.
The Heart Center conducts Cardiac
Risk Assessments, which include
blood pressure, HDL and total cho¬
lesterol, and glucose testing, as well
as recommendations for lifestyle
enhancements and a consultation
with a health care professional. The
Heart Center has done over 700 of
these free 30-minute screenings for
members of its community to date.
Formore information, please call 1-








Figure 7. Philadelphia Inquirer Magazine, March 25, 2001
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Investigators' skills improve subconsciously as the study progresses so
that small differences in the study variables, perhaps missed in the early stages, are
detected by the end of the end of the study. One investigator with whom I worked,
the late Walter Norris, MD, FFARCS. a consultant anaesthetist in Glasgow, would
revalidate annually his own study evaluation technique. In the 1960s anaesthetists
were evaluating oral forms of pre-anaesthetic medication to take the place of the
Omnopon and scopolamine by IM injection, and Walter had devised a rating scale to
assess the sedation and anxiolysis achieved. His first standard had been IM morphine
compared with IM placebo and each year he would repeat this comparison in a small
group of patients and compare the consistency of his current evaluations with those of
the first study, as a form of internal control. His repeatedly checked consistency was
the reason I asked him to perform evaluations of IM and oral pentazocine (285, 286).
f) Assay Sensitivity: an absolute necessity
There is no clear indication as to who was the first to use placebo as a control in
clinical studies. As long ago as 1801 John Haygarth, describing a traction apparatus,
reported what may have been the first placebo-controlled trial and noted the 'wonderful
and powerful passions of the mind upon the state and disorder of the body.' (287).
Flint gave his placeboic remedy in order to study the natural course of the disease and
noted that it worked (57), but this was not a controlled trial. Shelley, an Edinburgh
graduate and former Winthrop colleague of mine, has suggested that Martini was the
first to recognise the need for placebo to control extraneous variables in order to obtain
valid comparisons (288). Gold, who edited the Cornell Conference on Placebo (66),
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was the first to emphasise the importance of placebo control to differentiate placebo
effect from pharmacological effect (289). He planned an evaluation of treatments for
angina pectoris and at first he attempted to enroll only those patients who could
distinguish glyceryl trinitrate from placebo. Unfortunately, he found that a large
number of his patients obtained benefit from both and that they could not separate the
active drug from the placebo.
The first use of placebo as a concurrent control came in 1938 in a study of
vaccines to treat the common cold (290). Using students from the University of
Minnesota, the investigators compared the prophylactic effects of a vaccine, given by
subcutaneous injection or by mouth, with those of matching placebo given by injection
or by mouth. At the conclusion of the study there was a small advantage for the
vaccine, a difference which, although statistically significant, was so small as to be
deemed by the investigators to be of no practical relevance or value. In the discussion
which followed Dr. W.A.Sawyer commented that many physicians claimed that 50 -
70% of their patients remained free from cold after receiving the vaccine, but these
claims were based on a few cases and an absence of controls, while he himself had
been guilty of jumping to the conclusion that because patients reported no colds after
taking the vaccine this was probably the result of the vaccine. He expressed a debt of
gratitude for this valuable investigation with controls.
As we have seen, superiority studies showing clearly that the new treatment is
better (or worse) than the control treatment, are the easiest to interpret. With
noninferiority studies, showing the new treatment to be not worse than the control
treatment is less helpful because both could be equally effective or equally ineffective.
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Henry, a former classmate of mine, has quoted Robert Temple MD, of the FDA,
describing such a situation by saying, Tf the new drug seems indistinguishable from
the active control you don't really know what you have got.' (144). Lasagna (136)
discussed the difficulty when the new treatment seems to be inferior, writing, '..in the
absence of placebo controls, one does not know if the inferior 'new' medicine has any
efficacy at all, and equivalent performance may reflect simply a patient population that
cannot distinguish between two active treatments that differ considerably from each
other, or between active drug and placebo.' Exactly what was found by Gold.
Temple has for many years been a Senior Division Director at the FDA, and has
access to the data from all new drug submissions that come to his Division, a number
far in excess of any that a physician in a pharmaceutical company will ever see, so his
opinion is to be heeded and valued. In discussing the use of active control treatments
in equivalence trials (ACETs) he has stated that to conclude a new treatment is
effective because it is similar to control assumes that the active control was effective
and would have been superior to placebo. Support for this must come from outside
the study, that is, previous comparisons with placebo (277). If we are not confident
that the trial could have separated active drug from placebo then we cannot be
confident that it would have separated a more effective drug from a less effective drug.
The FDA experience shows that of all modern antidepressant studies submitted
by the manufacturers, a third to a half fail to show separation of a known effective
drug from placebo. Results from studies of treatment for depression are difficult to
interpret because drug effects tend to be delayed and the spontaneous improvement
rate is high: these problems do not arise in studies of responsive cancer or infectious
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disease, for example, two therapeutic areas in which the critics claim no one would
contemplate using a placebo, but they might be wrong. No one denies that to use
placebo as the only treatment for patients in such studies would be unethical, yet new
treatments for these therapeutic areas deserve the same rigorous evaluation as any
other if bizarre episodes such as the laetril debacle are not to be repeated. Placebo
controls are needed even here, but the study design has to be more imaginative to
prevent any harm arising as a result of its use.
g) Placebo effects are not constant
Beecher's seminal publication (94) propagated a myth that the placebo response
is constant in approximately one third of patients. This occurred because Beecher
averaged the response rates from his 15 studies and emphasised this figure.
Subsequent misreading and misquoting of the paper perpetuates the myth that about
33% of patients in pain will always respond to placebo, and yes, I am guilty also, but
I am in good and substantial company. Evans (291) has added to the myth by
quoting data from a further 13 double blind studies of analgesics and showing an
average placebo response rate of 36%. The error of interpreting the data as an
average, rather than as a median, has been pointed out by others (287, 292, 293).
The danger thus created is twofold, first it obscures the most important finding,
namely that there is a range of variability to placebo response in the different analgesic
studies, from 15 - 53% in Beecher's studies and 7 - 37% in those discussed by
McQuay et al. (293), and second it suggests that the placebo response rate is
constant.
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Other disease states in which there is a subjective overlay, for example in
psychiatric studies, show a similar pattern with the placebo response in depressed
patients ranging from 0 - 68% and from 35 - 76% in patients undergoing
psychotherapy (294, 233). In a review of studies involving ondansetron, an anti
emetic used in post surgical patients, it was found that the active drug was no better
than placebo in 19/52 studies, with success rates in the range of 1 - 80% for those
who received placebo and 10 - 96% for those who received ondansetron (222).
These studies showed an overall efficacy for the active drug but in several of the trials
the incidence of nausea and vomiting was so low, or nonexistent, that there was no
opportunity to show a drug benefit. Had these been ACETs without the placebo
control, interpretation of the results would have suggested equal efficacy from the two
treatments, a classic Type II error.
h) Can placebo responders be predicted?
It would be surprising if Beecher's group in Boston had not considered this
possibility, and indeed they did so (231). Using psychological tests, they were able to
identify some differences in attitude, habits and educational background between
those who had reacted to placebo and those who had not, but they also found a total
inconsistency of responses following both single and repeated doses, and could not
predict the reactors in advance (295). They suggested that this probably reflected the
operation of multiple factors in the determining the placebo response, since it was
unlikely that the patient's personality was changing so rapidly in such individuals.
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There is general agreement that, despite many attempts by different
investigators, it is not possible to predict placebo reactivity (296), to specify patient
characteristics, particular study populations, treatment protocols or sample sizes that
will consistently identify or allow predictions as to who will or will not respond to
placebo treatment (277, 297). Patient expectations clearly have an effect (122) as
we have seen. Others have concluded that response to placebo cannot be predicted,
either for groups, patients or healthy volunteers, and that no 'clear, typical "placebo
reactor" has been found.' (298).
Beecher was aware that his averaging of results in his early paper was regularly
misquoted, and some time around 1970 - 71, in Hyde Park as we attempted to walk
off the effects of lunch at Boodles, he mused that not only was it impossible to identify
or predict who would respond to placebo, he had also changed his assessment to
believing it likely that all of us respond to placebo, but inconsistently, given the
changing circumstances and alterations in the impact of the various components of the
placebo response at any one time.
i) Some differing opinions
Rothman (145) concedes that a placebo provides control for non specific effects
which are often highly variable, but so long as two active treatments can compared in
a blind assessment he challenges the need for a placebo group. He does not discuss
how this is to be achieved if the active comparator is marketed and formulated with an
unique identification, but if the presentation is to be altered to provide the matching to
maintain the double blind there may be substantial alteration to the PK and thus the PD
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characteristics (299). It is possible to leave the marketed formulation unaltered and
have all evaluations and assessments performed by an observer who has no knowledge
of the treatment allocation (300), but strictly speaking this then becomes a single blind
study because the patient and the prescribing physician are well aware of the identity
of the treatment.
Despite the slightly misleading title of their paper, Henry and Hill (144) accept
that the placebo controlled studies 'generally provide us with good evidence that the
drug works under specified conditions.' Their request for ACETs comes from the
Australian requirements to show comparative cost effectiveness for new drugs:
obviously this can only come from comparison with marketed, active controls, but will
they be satisfied with equivalence studies lacking assay sensitivity or will "no evidence
of difference" be construed as "evidence of no difference"? Simon (301) believes that
Rothman's claims overlook many of the problems of data interpretation from clinical
trials particularly those trials involving active controls with limited or inconsistent
efficacy, and in the absence of assay sensitivity, such trials might be considered
unethical, comments with which I agree.
A final comment is thrown in by Michels (146) who reportedly stated that
'Nobody would think of using placebos for such treatable diseases as cancer and AIDS.'
She was referring to placebo controls in trials and not to the treatment of these
diseases, but as we shall see, she is wrong, people do, they most certainly do.
I wonder if, in their haste to condemn the placebo control as a fixation with
statistical significance on the part of the FDA, Rothman and Michels are showing a
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willingness to accept conclusions that cannot be verified because the measurements
lack confirmation of sufficient assay sensitivity? They seem to have fallen for a
common syllogism by believing that if a drug was once shown to be superior to placebo
it will always be superior to placebo so there is no need to have further placebo
controlled studies with this drug. By extension, if any other drug is shown to be
noninferior to the first then it can also be considered to be superior to placebo and so,
without equipoise and this certainty, any such comparison of the second drug with
placebo is unnecessary and unethical.
I noticed that recently Hearts were able to defeat Dundee United by 2 - 0, and
the next week United beat Rangers by the same score. Using Rothman's syllogism it is
obvious that, two weeks later Hearts should easily beat Rangers and earn three points
— but alas, they lost 0-1. Perhaps the combined impact of different times of the
comparisons, the different venues, the different participants and the different
observers was to blame. Under more 'controlled' circumstances, I recall in 1956
watching with great delight as the Hearts defeated Rangers at Tynecastle, by 4 - 0,
on their way to winning the Scottish Cup. The next year, as a result of the luck of the
draw, I watched the same two teams meet again, on the same ground and in the
same competition with most of the same players, but this time it was Rangers who
won, also by 4 - 0. Same teams, same ground, same competition, same observer,
same score but a totally different outcome and, as might be imagined, a totally
different response from the observer! What would Walter Norris make of this?
We need to be cognisant that, for rigorous, scientific evaluations of new drugs
and treatments, direct comparisons are necessary and that they do not always provide
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outcomes that match predictions and expectations. Even if there have been previous
studies using placebo, further placebo controlled trials may be required to provide
assay sensitivity, particularly if other relevant outcomes appear or have not been
adequately evaluated, or if different observers, measurement techniques and
assessments are being employed.
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XII. SPECIFIC STUDIES: INCLUDING SOME OF MY OWN.
a) Analgesics and anti-inflammatory drugs
i) Not so good
The first study that I helped to design and monitor compared
benorylate, an ester of aspirin and paracetamol, with aspirin, at that time the
treatment of choice for patients with rheumatoid arthritis (302). A previous study
using the third molar dental pain model had shown benorylate to be superior to
placebo. In several respects ours was a well designed study embodying many of the
points that have been raised thus far, but it had a fatal flaw. Dr. Bain, the
rheumatologist, even undertook a small pilot study with benorylate which developed
familiarity with the protocol and confirmed that a dose of 4g. daily was an effective
analgesic in rheumatoid arthritis.
To remove the problem of inter observer errors there was only one
observer and the duration of treatment was four weeks, to minimise natural disease
regression to the mean. There was a treatment free run in period of one week then
patients started the double blind, random allocation of study treatment. After two
weeks patients could increase the dose of the study drug if they so wished. At the end
of the study 29% (4/14) of the patients who received benorylate had increased their
dose compared with 54% (7/13) of the patients who received aspirin. This was the
only objective difference between the two treatment groups. Subjective improvements
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were seen in the reduction of the duration of morning stiffness and increase in grip
strength, but these were of equal degree in both treatment groups.
In the absence of a placebo group the study lacked any internal assay
sensitivity so we were left to conclude that the new drug appeared to be as effective as
aspirin at the doses used, but questions remained. Could this have been a Type II
error or were both drugs genuinely equivalent? With the benefit of hindsight and more
experience I wonder if the study was truly ethical, given that the design made a
definitive result unlikely. Incorporation of a placebo would have been considered
ethical because of uncertainty concerning the efficacy of the new drug, the duration of
exposure was sufficiently short for no harm to come to the patients (263, 303) and at
that time the first line of treatment in RA was aspirin or other mild anti-inflammatory
drugs such as ibuprofen. At this distance I cannot recall if we considered having a
placebo treatment arm, but the omission proved to be a major disadvantage.
ii) A better effort
The reformulation of naproxen using the IPDAS® system and the results
of an analgesic study have already been described (272), but it was expected that this
formulation would be used more widely for the treatment of osteoarthritis (OA) and
rheumatoid arthritis (RA). The objective was not to prove that naproxen was an
effective analgesic and anti-inflammatory drug, that had been known for 30 years, but
to ascertain whether or not the new reformulation altered or impaired the drug
performance.
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Two identical studies were undertaken (304, 305), one in OA and one
in RA with study participation for 12 weeks. After a run in period during which all
patients received placebo, they were randomly assigned to receive either Naprelan
once daily, Naprosyn twice daily or placebo twice daily. The Naprelan treated patients
also received a placebo tablet in the evening, using the matching dummy technique to
maintain the double blind. In both studies, global assessments of disease state by the
physicians and patients, joint pain and stiffness showed significantly greater
improvement after one week of treatment with the active drugs compared with the
placebo. At the end of the study, after 12 weeks of treatment, both groups that
received the active drugs showed significantly greater improvement than did the
placebo treated group. In addition, the OA patients who had received active drugs
required significantly less 'rescue' paracetamol compared with the placebo treated
group, and in the RA study, the 'marked responder analysis' (306) showed significant
advantages for the patients who received the active drug. For all assessments in both
studies the two active drugs were equivalent, except in the RA study where pain relief,
evaluated during the day and into the evening as a check on the continuing efficacy of
the once daily Naprelan formulation, showed Naprelan to be significantly superior to
both Naprosyn and placebo.
I had not taken part in the design of this study but I became responsible
for the data analysis and presentation. Ethically, there was justification for the study
with genuine uncertainty over the efficacy of the two part release system in the
formulation, the time to onset, and duration, of action being paramount. The
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placebo run in period for each patient was of particular significance in this study
because of the need to assess onset of action of the new formulation. It was essential
that any effectiveness observed in the first week of study treatment come from the
study drug and not as a carry over from the previous therapy, which has been shown
to occur (307). Thus, the run in was continued only until the complete absence of
previous active treatment was shown by the flare in disease state. The inclusion of
active comparator and placebo groups provided assay sensitivity for the comparison of
two active drugs, as we had used previously (268).
iii) Measuring dose responses
In an attempt to identify the most useful oral dose of pentazocine, a
study (308) which I did not design but monitored, compared four doses of the drug,
25mg, 35mg, 50mg, 70mg, in patients in general practice. No placebo was included
and the results showed no significant differences between the three larger doses, with
35mg and 70mg being indistinguishable. The 50mg dose was only marginally more
effective than the 25mg dose although it was better tolerated than the 35mg and 75mg
doses.
These data did not prove to be helpful in answering the question as to
which dose should be developed further, so to obtain a clearer assessment I designed
a second study. This compared single doses of 50mg and 70mg, and included a
placebo, in patients who had undergone abdominal or thoracic surgery, but were now
able to take oral analgesics, and once more I asked my anaesthetic colleague to help
(309). The results are shown in Figure 8 and a statistically significant trend of
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increasing effectiveness with increasing closes is seen. It is interesting that both doses
of the active drug were ineffective in 30 - 35% of the patients, confirming again that
even pharmacologically active drugs are not effective all the time in all patients, and
that an inert, lactose placebo was partially effective in 25% of these patients who were
in moderately severe pain. Although not shown in the Figure, there was also a dose
response effect seen in the incidence of adverse events with 8%, 13% and 26% of
patients reporting events in the placebo, 50mg and 70mg treated groups,
respectively. The placebo provided the required assay sensitivity that confirmed these
results as valid, and after the injectable formulation of pentazocine had been marked it
was the 50mg oral tablet form that was developed.
Analgesia Obtained by Patients in
Moderate Pain (expressed as percentages)
Treatment Pain Relief Total
0 1 2
Placebo 75% 25% 0% 100%
Pentazocine 50 mg 30% "*49% 21% 100%
Pentazocine 70 mg 35% 23% "*42% 100%
Total 43% 34% 23% 100%
Key: 0 == nil 1 = partial
2 = considerable or complete
Figure 8
Reproduced from reference 309.
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iv) Comparisons with effective drugs still need placebo
As we have seen comparisons with effective, currently used
comparators are required and that some critics believe that these should be the only
comparisons performed (144, 301). However, if we are to avoid the problems
already discussed at length, and ensure the validity of the study results, then placebo
is still required for assay sensitivity.
When the NSAIDs were shown to be effective analgesics for women with
dysmenorrhoea we thought that it would be useful to compare fenoprofen with
ibuprofen, one of the first of the modern NSAIDs, and placebo, in a double blind,
randomised study (310). The results showed that fenoprofen 200mg and ibuprofen
400mg were equivalent and both active drugs were more effective than placebo, as
assessed by the patients' reported pain scores. Internal assay sensitivity in this study
was provided by the placebo so the results could be considered valid, and that these
doses of the active drugs were genuinely of equivalent efficacy.
Following this study we wondered if a larger dose of fenoprofen would be more
effective, so a second four arm, double blind, randomised study was designed,
comparing fenoprofen 400mg with aspirin 650mg and placebo, with a fourth arm being
fenoprofen 200 mg, again, to check and confirm the superiority over placebo seen in
the previous study (311). Thus the study combined double assay sensitivity by
inclusion of the placebo and two different doses of the drug under evaluation. The
results showed several interesting aspects. Using the patients' reported pain scores,
fenoprofen 200mg and 400mg were equally effective, with no significant difference
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between them, but both were significantly more effective than aspirin and placebo,
the latter two being indistinguishable.
The similarity in effect between the two doses of fenoprofen might seem
like a possible Type II error or the result of inadequate sample size in the study, but
the significant separation from placebo confirms the validity of these results. In fact,
these findings indicated a plateau effect with increasing doses of fenoprofen. This led
to the clinically useful recommendation that if 400mg. of fenoprofen fails to benefit a
particular patient then it may be more appropriate to switch to another NSAID rather
than simply increase the dose of fenoprofen. That aspirin was no more effective than
placebo came as no surprise to the gynaecologists who performed the study as
apparently they had been aware of this for many years.
v) Add on placebo comparison with standard therapy
Patients with sickle cell disease have frequent vaso-occlusive crises
which are excruciatingly painful and in many US Hematology Centers the standard
treatment is IM injections of pethidine. The investigators were concerned about the
attendant secondary opioid effects of constipation, respiratory depression, injection
site fibrosis and addiction potential which accompanied chronic and repeated use of
pethidine, and they had previously evaluated an oral NSAID in the treatment of these
patients, hoping that the analgesic properties and the inhibition of platelet aggregation
by this class of drugs might be more advantageous. Unfortunately the results had
been disappointing, raising the question as to whether the NSAIDs as a class were not
effective analgesics in this setting or whether the problem was the oral administration
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of the drug. With this experience there was considerable uncertainty as to the value
of an injectable NSAID, ketorolac, but this seemed to be worth studying. It would
have been cruel and completely unethical to treat these patients with placebo alone so
an add on design was used for a double blind, randomised study to compare ketorolac
with placebo (312).
In the study centre the routine analgesic care for patients with sickle cell crisis
was IM pethidine at least every three hours or on demand, until relief was obtained,
and as these were regular patients at the centre all were familiar and experienced with
this regimen. There was no question of withholding standard, best available care.
On enrollment to the study patients received either a continuous infusion of
ketorolac or placebo (normal saline) allocated at random, and their injections of
pethidine as per usual practice. The results as measured by reduction in pain intensity
showed that ketorolac plus pethidine was significantly more effective than placebo plus
pethidine. More striking, perhaps, was the finding that patients who received
ketorolac required 33% less pethidine than their counterparts who received placebo
plus pethidine. Recalling that all patients were used to receiving pethidine every three
hours, they were asked to comment on the combination that they had just received
and again the ketorolac plus pethidine was significantly preferred over their usual care.
The most surprising finding was that the patients who received ketorolac, on average
spent three days in hospital compared with the other group who spent, on average,
seven days in the hospital. A survey of the hospital records for all the patients in the
study showed that previously their average stays in hospital had been about seven days
also, providing confirmation that in this study there was no Hawthorne effect and the
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group who received placebo plus pethidine were not responding in an abnormal
manner.
The use of the add on technique permited all patients to obtain standard
effective therapy in a clinical trial of a new drug and also allowed a comparison with
placebo to provide assay sensitivity. There can be no doubt about the validity of this
study and no criticism that one group of patients were denied standard, effective
treatment.
b) Placebos and infectious disease
Growing concerns with resistance resulting from inappropriate antibiotic overuse
are being increasingly addressed (313) and despite the assertions of critics placebo
controls are used in clinical trials involving patients with infectious disease where the
risk of mortality and morbidity are minimal.
i) Treatment with antibiotics
A study comparing aureomycin and placebo in military recruits with
coryza showed that after 24 hours of treatment 44% who received the antibiotic had
improvement or cure compared with 45% of those who received placebo (314). A
more recent, similar study compared an antibiotic combination with placebo and
showed that 34% of the patients with coryza were cured in five days regardless of
which treatment they had received (315).
A pediatric study comparing amoxicillin and placebo in children with
acute otitis media showed that after four days the children who received the antibiotic
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had significantly fewer symptoms than did those who received placebo, but after 11
days both treated groups had the same rate of clinical failure (316).
ii) Prophylaxis and placebo
Low dose antibacterial prophylaxis for patients with recurrent urinary
tract infection (UTI) came into vogue about twenty years ago and I designed a study to
compare cinoxacin, then recently introduced, with placebo. This might have been a
study in which the critics would demand an active comparator, but UTI is not
immediately life threatening, the patients were seen at regular intervals for urine
culture and there was minimal risk of an infection actually going untreated, so it
seemed that the benefit of assay sensitivity was worth obtaining (317). Patients who
had suffered at least three UTI in the previous year but were free of infection on
enrollment, received either cinoxacin 500mg once daily or placebo. After 220 days of
treatment 90% of those who received the antibacterial drug were asymptomatic and
microbiologically clear, compared with 52% of those who had received placebo.
I had no involvement in a second pediatric study (318) of malaria
chemosuppression but it was of interest to me because it was performed in an
emerging country, used a double blind, randomised design with placebo control and
involved proguanil. All the children had initial curative therapy with atovaquone plus
proguanil and were free of P. falciparum and P. ma/ariae at the start of the
chemosuppression phase. They then continued to receive the combination product,
at one fourth of the dose, or placebo, for 12 weeks. At this time 25/140 of the
children who received placebo had positive blood smears for parasitaemia compared
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with 0/125 of the patients who had received the active combination, leading the
authors to conclude that this combination should replace current regimens to which
resistance was becoming more common.
Results from the studies described above that had assay sensitivity offered
proof that prescribing of antibiotics for coryza is an ineffective exercise which is
specifically not recommended (319), but that early antibiotic treatment in pediatric
otitis media offers the advantage of rapid symptom resolution. Prophylaxis for UTI
and malaria, together with identification of a more convenient and equally effective
dosage schedule or a combination associated with less developed resistance, would
seem to me to be worthwhile information that has direct clinical application, but would
these results stand up to scrutiny without the assay sensitivity provided by placebo or
totally objective measurement?
iii) Different treatment schedule
In another study of UTI we were interested to learn if the standard dose
of cephalexin, lg daily, would be as effective if given in the more convenient schedule
of twice daily rather than four times a day (320). As the assessment was to be
entirely objective, based on urine culture and the microbiological response, the same
drug in the same dose was being evaluated and because untreated UTI is associated
with significant morbidity, we did not believe that a placebo comparison was justified
in this study. Results showed that the microbiological cure rate was 93% in the
patients who took the drug twice daily and 91% in those who took it four times daily.
The results from this study, together with other similar studies, resulted in a change
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to the product prescribing information, in which the more convenient, less frequent
dosing schedule was recommended for the treatment of uncomplicated cystitis (and
skin infections, which were studied later).
iv) Add on placebo for AIDS and transplantation studies
As Michels points out, of course no one would countenance using a
placebo as sole treatment in studies of these diseases. However, the add on
technique can be used and placebo plus best supportive care has been suggested as
inevitable for the reliable assessment of the benefit-risk ratio in these life threatening
diseases (321). Although not particularly informative about the use of the new
treatment as monotherapy, this design is appropriate if the new treatment is likely to
be used in practice as part of combination therapy (277). As the laetril debacle in
cancer patients showed, there are also ethical concerns over the recommendation of
useless nostrums that have never been properly evaluated or have shown efficacy only
in poorly designed, anecdotal investigations that lack both controls and assay
sensitivity.
I had nothing to do with a major double blind, randomised study of over
1,000 patients with HIV infection, in which ritonavir, a new protease inhibitor, was
compared with placebo, using the add on technique (322) but this shows that placebo
can, and is, being used in trials of these serious diseases. All the patients continued
to receive their standard HIV therapy which could include up to two nucleosides
(zidovudine and stavidine were used by 71% of the participants), and to this was
added either ritonavir or placebo, allocated at random. Any patients who developed
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an AIDS-defining outcome, for example CMV retinitis, were switched to open label
ritonavir while those who did not develop this outcome remained on the blinded study
medication. At the end of the study all patients received ritonavir on an open label
basis.
Addition of ritonavir reduced the risk of AIDS-defining illness or death,
which occurred in 22% of the patients who received active drug and in 38% of those
who received placebo. On the risk assessment however, 21% of the ritonavir treated
patients withdrew from the study because of drug related adverse events compared
with only 8% of the placebo treated patients. Clearly the add on design contributed to
the knowledge base for ritonavir in the treatment of AIDS.
My therapeutic group was not directly involved in the studies of
mycophenolate mofetil (MMF), an immunosuppressant used to prevent organ graft
rejection but I was involved in the early phases of the trial design. Recognising that
the drug would never be used as sole treatment the add on technique was the only
choice if assay sensitivity was a requirement. Three trials were performed (323, 324,
325), all following the same principles of design and all using active drugs or placebo
as an add on to the supportive therapy of cyclosporin and corticosteroids. All the
patients had renal allograph transplants and two doses of MMF, 2G or 3G daily by
mouth, were evaluated.
The results were similar in all three studies with MMF 2G daily offering
the best protection against graft rejection and also being the best tolerated of the
active drugs. Rejection rates were greatest in the groups that received the standard
therapy plus placebo but patient withdrawal because of adverse events was the lowest
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in these groups. There is a high incidence of mortality and morbidity associated with
renal transplantation, but placebo was used to provide assay sensitivity in these
studies and contributed to the overall assessment of benefit and risk of the new
treatment.
c) Designs to limit placebo exposure
Provided that it is undertaken honestly and correctly, the informed consent
process should provide sufficient safeguards for any patient who agrees to participate
in a study, and for him or her to understand the need for and role of a placebo.
Nevertheless, investigators should not take advantage of these patients by expecting
them to tolerate pain or discomfort for prolonged periods, remembering of course,
that even therapeutically active drugs are not effective in every patient every time.
For these reasons designs to limit exposure to placebo have been considered.
i) Rescue medication
In most analgesic studies, patients are told that rescue medication is
available should the study drug fail to provide the required relief. During the informed
consent process, and at subsequent discussions, the patients should be encouraged to
give the study drug a chance to be absorbed, say waiting for an hour following an IM
injection and say two hours after oral ingestion, before they ask for rescue medication,
although stressing that they are free to withdraw at any time. Once the rescue
medication is given the patient has to be withdrawn from the study if it is a single dose
design, but if the study is of longer duration then requirement for repeated doses of
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rescue medication does not mandate withdrawal from the study. In fact, the
requirement for rescue medication can be used as a method of assessing comparative
efficacy. For example, in our study (268), 24/30 patients who received placebo
required rescue medication compared with 11/30 who received fenoprofen and 7/30
who received the IM morphine. The difference between placebo and both active drugs
was statistically significant while that between the active drugs was not, a further
emphasis of the assay sensitivity.
ii) Early escape
In some study designs a well defined treatment failure point is identified
and established in the protocol, say exacerbation of the disease beyond a defined
level, at which point the patient is withdrawn from the study and given the active
study drug in an open label fashion. This occurred in the ritonavir study when, at the
end of the second period assessment, 147/545 patients who received placebo and
79/541 patients who received ritonavir had developed an AIDS-defining outcome and
were switched to open label ritonavir (322).
iii) Post study treatment
In the ritonavir study all patients who had received placebo during the
study were ultimately treated with the active drug on completion of the formal study.
The protocol for the surgical implantation of foetal tissue in patients with Parkinson
disease stated that those patients who underwent the sham procedure would receive
the 'active' implantation after conclusion of the study (129). Unfortunately this did not
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happen for each patient, leading to substantial criticism and opprobrium being leveled
at the investigators (130, 131).
Whether or not placebo is involved, offering treatment beyond the
conclusion of the study is not common, and as an aside, this raises an ethical problem
in my mind. If a patient has responded well to the study drug, particularly for a life
threatening illness, say cardiac arrhythmia in which a new anti arrhythmic drug has
been evaluated, I believe that it is unethical for this treatment to be withdrawn simply
because the study has ended. Ideally, treatment should be made available for as long
as the patient continues to respond or the drug is marketed and thus readily available.
iv) Randomised withdrawal
If the desire is to compare a new and an established treatment in an
ACET, yet assay sensitivity is required, this design allows all patients to receive active
treatment to start with, but for placebo to be substituted for active drug in a double
blind fashion. The timing for the substitution is allocated at random so that patients will
continue with active treatment for different periods. This design provides information
on the duration of continued drug effect after it has been taken for different lengths of
time and then withdrawn. If any patient deteriorates the drug code can be broken,
the study drug identified and the patient switched immediately to active treatment.
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v) Planned withdrawal
A variation on the randomised withdrawal has also been described, in
part based on the paper by Gold (289) who found that only 4% of his patients with
angina who had coronary artery disease responded to placebo, compared with 25%
who responded to placebo but did not have coronary artery disease.
In this design (326) all patients entered a period of open label
treatment with the active drug, during which the dose could be titrated as necessary.
The protocol identified a time point at which all patients were to be evaluated. At this
evaluation, those patients who had failed to respond to the open label, active drug,
were removed from the study and treated in the usual manner. Patients who had
responded to the active drug then continued with the active drug or switched to
placebo, in a double blind, randomly allocated manner. The advantage of this design
is that all the patients receive active drug and those who fail to respond are not
exposed further, either to the drug or to placebo. The null hypothesis is thus tested
only in the second, double blind phase, enabling an assessment of the effects of the
new, active drug: were these genuine or a placebo response?
vi) Two doses of active drug
Provided that the two doses are sufficiently separated for any difference
in response to occur, this design can be used with an active comparator and no
placebo. However, if one of the doses is known to be too low to produce an effect
then this design involves self deception on the part of the investigator who claims that
all patients will receive active drug and that placebo is not involved. All the study
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drugs may indeed be active, but one group of patients is being denied effective
therapy. If there is genuine uncertainty as to the best dose then instead of
homeopathic doses of the active drug, why not use an inert placebo to provide assay
sensitivity, provide validity to the results and ensure that any lack of difference will be
not be casually accepted as equivalence?
vii) Unbalanced distribution
A compromise between the need for assay sensitivity and limited
exposure to placebo can be achieved by getting the statisticians to provide a random
distribution of the study drugs so that say, there are two or three patients who receive
the active drug for every one who receives placebo. Provided that the unbalanced
distribution is planned at the start and did not develop as an afterthought or as a
consequence of some failure of the patient enrollment or drug allocation process, my
statistical colleagues assure me that the data analysis is straightforward.
viii) Smoke and a mirror
One interesting study in which I was closely involved (327) concerned
the switch, from a prescription only to 'over-the-counter' non prescription status, of a
nicotine patch as an aid to smoking cessation. The FDA had requested placebo
controlled studies (a genuine instance of the regulatory authority making us do it!) and
also a study in which the participants would be asked to pay for the patch, to see if
payment improved the success rate. This would be a sort of an inverted Hawthorne
test in that the participants were not rewarded for increased performance but penalised
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by paying when they did not succeed. It was universally agreed that asking
participants to pay for placebo patches would be unethical, but the problem was how
to retain assay sensitivity for this group. The dilemma was solved by combining the
data from the two studies so that the placebo control group was a mirror for both the
groups that received the active nicotine patch.
In response to a newspaper or radio advertisement potential participants
telephoned a central service and, according to a random code, were told either about
the double blind placebo-controlled study or about the study in which they would be
asked to pay for the patches. If they agreed to take part in whichever study had been
described to them they were referred to the nearest study site for screening and
enrollment if suitable. Study personnel knew to which of the two studies each
participant had been assigned, but not the actual treatment in the double blind,
randomised comparison with placebo.
All participants were seen at the same sites with the same investigators
and study staff, in accordance with the study protocol requirements (328). Patients
were asked to record their smoking cessation in a daily diary and at each visit this was
checked biochemically using a carbon monoxide monitor. After treatment for six weeks
the point prevalence quit rates were 9.6% in the placebo treated group, 16.8% in the
group that received the active patch double blind and 19.0% in the group that received
the active patch and paid. After a further eighteen weeks without the patches the point
prevalence quit rates were 4.3%, 8.7% and 10.8% respectively in the three groups.
At both assessments the quit rates in the groups that received the active patches were
significantly greater than the quit rate in group that received placebo, but the 2%
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difference between the two groups that received active treatment was not statistically
significant.
All patients were told at the initial telephone interview that they had the
option of declining to participate in the study, so those who did choose to participate
probably were representative of the real world in which they would select patch use as
an aid to quitting smoking. Thus these were probably the best results that could be
obtained with the patch and the quit rates seen in the placebo treated group were
probably the lower limit for patch efficacy. The small difference in the quit rates seen
in the two groups who received the active patches suggest that there was no Hawthorne
effect in this study, and that paying for the patches was not a greater stimulus to
quitting.
ix) Historical control
In one of the hoariest cliches heard in connection with new drug
development the critic points out "No one needed formal trials to show that penicillin
worked.", ignoring that even so there was a comparison of sorts because the results of
treating infections with penicillin were evaluated against the results of previous
treatments in which an antibiotic had not been used because none existed. In the
1980s my therapeutic group was involved in a similar situation as the AIDS epidemic
took off.
Burroughs Wellcome (BW) and Syntex had both developed ganciclovir
which could be used to treat the cytomegalovirus (CMV) retinitis that rapidly led to
blindness in these immunocompromised patients. At the suggestion of the FDA, BW
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had started an initial Compassionate Use program in which all physicians treating AIDS
patients could obtain free drug. For business reasons, BW soon withdrew from the
scene leaving Syntex as the sole supplier and developer of the drug.
I became the Director of the therapeutic group into which ganciclovir
was placed and about this time my colleagues published their preliminary findings (329)
describing dramatic results in 26 patients with virologically confirmed CMV infections,
some involving more than one body system. Stabilisation of the disease was seen in
11/13 patients with CMV retinitis and 5/8 with CMV gastrointestinal disease. Of the
seven patients with CMV pneumonia, four died and the response in this disease group
could only be described as poor, but overall, these results made all conventional,
future comparative study designs unethical.
This publication was rapidly followed by three others, all concentrating
on the treatment of CMV retinitis, for which ganciclovir appeared to be particularly
effective (330, 331, 332), showing disease stabilisation and even some regression
of the retinitis in approximately 88% of the treated patients. These publications,
predictably, led to demands from the AIDS community that the drug be approved for
marketing so all the clinical data obtained up to this point, without any comparative
studies, were included in an new drug application to the FDA. The Agency, with
whom we had been working closely, recognised the difficulties involved and perhaps
would have accepted the study results for what they were, and approved the drug,
but the Advisory Committee were unimpressed. They recommended that the drug
application be rejected and that FDA and ourselves design further studies which would
incorporate comparator groups. The Committee members themselves offered no
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guidance on how these groups should be gathered nor what study design would be
acceptable to them, but in discussions with the FDA group we came up with two
designs.
We settled on one historical control design and a second study that
compared two different treatment regimens. The first study (333), at one site with a
large patient population, compared fundus photographs from patients who had been
treated either before ganciclovir became available or in the early days when doses and
dose schedules were at personal discretion, with photographs from new patients
treated prospectively according to a formal protocol. A standard for assessing disease
progression from fundus photographs, with gradings of new lesion, enlargement of
existing lesions and opacification of the border, was devised and all photographs were
read by a single ophthalmologist who was unaware of the treatment. Photographs
had the patient identity and date masked and coded and they were presented for
assessment in random order. Once each photograph had been assessed the scores
were sent to Syntex, the code was broken and the scores tabulated for each patient.
The results were convincingly in favour of treatment with ganciclovir,
but as always, there were questions over the systematic bias in selection and
comparability of the control group. For various reasons there had to be some selection
of patients, for example only those in whom photographs were available could be
included in the control group: there could be no random allocation of treatment:
there was no standardisation between the two groups as to intervals between diagnosis
of CMV retinitis and the start of treatment: there were different intervals between
evaluations of disease progression: some of the early treatments had been deliberately
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delayed and not all the patients had been photographed. In other words, the control
group was typical of an historical group collected post facto, and in the end, data from
67 potentially suitable patients had to be discarded.
The second study compared two groups of patients all receiving
zidovudine, with peripheral retinitis that was not immediately sight threatening, who
were prospectively treated with ganciclovir (334). Ganciclovir is by no means a non
toxic, well tolerated drug in all patients, particularly when given in combination with
other antiviral compounds. The uncertainty here concerned questions as to whether
immediate ganciclovir treatment, with zidovudine withdrawn, was more effective than
continuing with zidovudine until the retinitis had started to show progression. The
results showed clear benefit: immediate treatment with ganciclovir, in the absence of
zidovudine, delayed progression of retinitis by a median of 49.5 days, compared with
a median time to progression of 13.5 days in patients who received standard best
therapy of the time, zidovudine with ganciclovir therapy delayed. When these results
were submitted to the FDA and considered by the same Advisory Committee, the vote
to approve ganciclovir was unanimous.
However, historical control studies are always questionable because
there is considerable doubt as to whether the same diagnostic criteria were used to
identify the control group. Are patients who were previously excluded now entered
because of a change in disease diagnostic definition or the advent of new diagnostic
techniques? If an important variable was not recorded for the historical group does
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that mean that it was absent, or simply not measured? Absence of evidence cannot
be assumed to be evidence of absence. If multi therapeutic regimens are required,
say the anti cancer regimens, have the components been changed since the control
group was treated? However, as with penicillin, when there is evidence that a new
treatment can prevent or delay the onset of serious complications, the ethical
justification of comparative study designs becomes problematic. Falling back on an
historical control may be the only choice.
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XIII. PRIMUM NON NOCERE: PLACEBO REDUCES THE RISK!
In his attack on placebo controls in clinical trials Professor Rothman admits that
'Because the placebo effect is usually considerably different from that of an effective
treatment a study does not have to be very large to find a significant difference.' (145).
To admit to this advantage for placebo is an enormous concession from one of the
strongest critics and endorses the need for placebo controls in studies that are seeking
proof of concept. If the new drug really does not work at all then this should be
discovered as quickly as possible while exposing as few patients as possible to
ineffective therapy, while still remembering that even effective drugs do not work in all
patients all the time, despite Dr. Michels' apparent beliefs.
Using data from a recent paper by friends and colleagues in the Oxford Pain
Relief Unit (293) let us accept a placebo response rate of 37%, and a hoped for
response rate from a new analgesic of say 75%. To show a difference between the
two treatment groups at the 5% level of significance will require 15 patients per group,
of whom 10 (63%) of those who receive placebo and 4 (25%) of those who receive the
new drug, that is a total of 14 patients, will not obtain effective analgesia, yet the
study objective of proof of concept will have been achieved.
If now we take an established analgesic which, using the Oxford data, might
be effective in up to 63% of patients (recall that the study with oral pentazocine (309)
showed a response range of 65 - 70% for the two doses) and compare it with the new
drug which is again effective in 75% of the patients, 150 patients per treatment group
will be required to demonstrate a statistically significant difference at the 5% level. Of
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these, 56 (37%) who receive the established analgesic and 38 (25%) who receive
the new drug, that is a total of 94 patients, will not obtain effective analgesia. This
seemed to me (335) to be a disappointingly large number of patients on which to
inflict the torture of pain that Rothman agrees is not a good idea (197) but it is the
price that has to be paid in order to assess comparative efficacy with best available
treatment rather than placebo. Should the difference between the new analgesic and
standard therapy be less marked, say a response rate of 70% for the new and 65% for
the standard, which was in fact the difference between the two doses of pentazocine
in our study (309), then approximately 500 patients per group will be required to show
this as a statistically significant difference, with a total of 325 patients obtaining
inadequate analgesia. With approximately one third of the patients showing no
response to treatment and in the absence of assay sensitivity, could this be a valid
result or an error of Type I or Type II?
The late John Harter, MD. who was the FDA Division Director
responsible for the approval of analgesic and anti inflammatory drugs, and who was
prominent in the rewriting of the Guideline for the Evaluation of Analgesics (217),
applied a simple proof of concept test. Tf,' he said, 'your new analgesic cannot be
shown to be significantly better than placebo in a study of no more than 30 patients,
who needs your drug?' Actually, his comment seems to ignore the extreme variability
in placebo response, ranging from 25 - 60% depending on the study and disease
being evaluated, but this itself is a reason for always including a placebo control.
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XIV. PLACEBO REDUX
As the Art of Medicine gives way to the Science of Medicine and Evidence-
Based decisions dictate the choice of drug or treatment for our patients, there are loud
demands that all new therapies undergo rigorous scientific evaluation before being
approved for marketing. From this it might be supposed that the need for assay
sensitivity would have universal acceptance, but apparently not.
We have seen that since earliest history placebo has been on a roller coaster
ride as it passed from being a word of respect to a major role in a religious ceremony,
through derision in the Middle Ages to widespread use, if not publicity, in the practice
of medicine, to a role in modern medical research. Definitions in medical dictionaries
do not always provide consistent help in interpretation or understanding and members
of the medical profession have seemed to be unsure of what role, if any, placebo
should play. Some senior physicians have openly proclaimed the usefulness of placebo
in their practice while others have been more diffident and perhaps regarded it as akin
to charlatanism. Even today there appears to be considerable confusion as to what
placebo is. In an exercise that owed something to the comments of Dr. Pepper, 318
published articles with the words 'placebo' or 'untreated' in the abstract, were recently
evaluated (336). In 188 of these articles the word 'untreated' did not refer to an
untreated control group. In the remaining 130 articles, 52 used 'untreated' as
synonymous with placebo, and differences between the placebo itself and the placebo
effect, or response, seem to pass unrecognised.
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Thus, it has been easy for Rothman and Michels, with their fellow critics, to
make sweeping statements about placebos to stir the emotions and cloud the rational
appreciation of what is being said. Their major criticisms appear in 3-D, namely
Denial, Disregard and Deception and perhaps should be addressed briefly once more.
Denial of effective therapy and reduction in quality of life are usually cited first,
but we know that individual patients do not always respond equally even to the so
called standard doses of drugs, although this is more often disregarded than
investigated and explained (123). As Dundee graduate Alastair Wood wrote recently
(337), this inability to understand and predict the variability in patient response to
treatment means that our prescribing of drugs is an iterative process in which
treatment is started with the standard dose and then titrated up or down depending on
the therapeutic response. Thus patients may receive ineffective therapy for varying
periods, even from an effective drug given with the best of intentions. True, placebo
may lack a specific therapeutic effect but it is a powerful intervention (338), and even
Rothman acknowledges that it has the advantage of reducing the numbers of patients
in a clinical trial put at risk of receiving ineffective therapy.
Critics claim that patients in studies of antidepressant or anxiolytic drugs are at
a greater risk of committing suicide if they remain 'untreated' by receiving placebo, but
a review of the data from controlled trials submitted to FDA found no increase in
suicide or suicide attempts among placebo treated patients, and conversely, a review
of national suicide rates has shown no decrease in suicides among depressed or
psychotic patients who were treated with currently available 'effective' drugs (339).
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Using a placebo comparator puts fewer patients at risk, as I showed in the analgesic
example.
Michels seems unable to recognise that even when they achieve a satisfactory
therapeutic response the quality of life of patients receiving active drugs can be
markedly diminished by the appearance of adverse events such as nausea, vomiting
and constipation. For example, cancer patients often complain that the constipation
caused by opioid administration is more troublesome than the pain the drug is
supposed to relieve. She also ignores the other more severe and serious secondary
pharmacological effects that may occur, such as cardiac arrthymia or blood dyscrasia,
neither of which have been reported with placebo treatment.
Disregard of patient autonomy and beneficence is the second criticism, but this
applies to any and all trials and not just to the use of placebo. Clinical trials are
experiments designed to elicit a particular answer from a comparison of groups of
patients, with consequent restrictions in catering for individual response. Patients
must be informed before they are enrolled in a trial, but if they agree then presumably
they understand what they are giving up in the way of autonomy.
The third criticism is Deception of the patient by placebo substitution, but this
occurs only if the informed consent process is incomplete, ignored or dishonest. If,
after a full and comprehensible explanation that a placebo will, or may, be introduced
at some time unknown to the patient or investigator for the purpose of separating
perceived placebo effects from placebo effects themselves and to validate the study
results by providing assay sensitivity, and the patient still agrees to enter the study, I
see no problem with the 'deception.'
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The critics seem to forget that that we welcome and enjoy 'informed' deception
in our everyday life. We are entertained by magicians and illusionists when they
perform their tricks. We read detective stories and are delighted when we can
successfully unravel the deceptions perpetrated by the author and identify the culprit,
we go to the theatre, watch television or a film knowing that we are being deceived,
that things are not necessarily what they appear to be, that the actors are not really
killed or buildings spectacularly destroyed. We admire the work of stunt men who
perform the tricks and we ponder the manner in which the deception is created, so
that the deception is part of the enjoyment. Some patients may even derive the same
pleasure from the study if they understand the nature and reason for the deception,
but, failure to disclose the placebo means there is no 'informed' deception. This is
unethical and indefensible.
It was a pity that shortly after publishing the instructive series of papers on
aspects of placebo use, Lancet adopted a general policy of not accepting papers that
describe placebo controls when an effective treatment is known to exist (340). Does
this mean that the Editor believes that the only way to include a placebo is as sole
therapy in the comparator group? If so then it seems to show a lack of appreciation
that there are many different study designs that include placebo to provide the assay
sensitivity and do not deprive the patients of effective therapy at the same time. If
there are to be no placebo controls will Lancet accept reports of studies involving
untreated control groups? While it is possible to have the patients allocated at random
to study treatment or to no treatment, but it is not possible to make this double blind,
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as scientific rigor requires, and there can be no doubt that the untreated patients will
be denied effective therapy.
The Lancet Editorial stance is at variance with the recently published E10 report
from the International Conference for Harmonization (341) which accepts as ethical
the use of placebo-controls in clinical trials even if an effective treatment is available for
the condition. The report contains the caveats that the placebo use must be for short
duration only, that patients are unlikely to come to serious harm from the withholding
of specific treatment and that full information is provided to the patients about
available treatments outside the study and the possible consequences of delayed
treatment. It is also relevant to note that the International Conference is comprised of
representatives from the regulatory authorities and the pharmaceutical industry in
Europe, Japan and the USA. In this recent report the ICH revisit the earlier list of five
possible choices for control groups (215, 216) and add a sixth choice, Multiple
Control Groups (paragraph 1.3.6) which has a placebo control in addition to an active
drug control.
Critics demand maximum scientific rigor in the evaluation of new treatments
with the double blind, randomised design, but they fail to consider the practical
aspects of these demands, such as how the blinding of the study drugs is to be
achieved when a marketed comparator is selected as the active control. Obviously the
marketed formulation cannot simply be changed to match the new drug, nor can the
latter be prepared to look like the marketed comparator, particularly if there are
identification marks on the marketed drug. The easiest technique is to formulate the
new drug as an opaque capsule and then put the marketed comparator into a matching
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opaque capsule. However, frequently this over-encapsulation changes the PK and PD
characteristics of the comparator drug and at the very least this requires a PK study to
be undertaken to show that there is no alteration in these characteristics. Overall the
placebo offers the best and most flexible options for matching formulations to maintain
the double blind, even if the double dummy technique has to used on some occasions.
If the double blind, randomised clinical trial is truly the gold standard for drug
evaluation then incorporating a placebo comparator, in one design or another, is
necessary to provide validity of the results and for a reliable assessment of the benefit
risk ratio (319, 342, 343). Among the scientists involved in the development of new
drugs, the reviewing officers in the various regulatory agencies and the committees
who evaluate the clinical trial data, there is a shared desire to have scientifically
rigorous, assay sensitive and validated, clinical assessments and comparisons. That
means placebo control, not necessarily as a sole therapy but in some form and using
one of the more imaginative designs such as add on, or timed withdrawal, if these are
appropriate. There is also a need to educate the medical community about the role of
placebo and the separate area of placebo effects, often perceived merely as 'noise' to
be eliminated without any understanding as to how these potentially desirable effects
play a role in every interaction between patient and physician, or how they can be
used to benefit the patient (336). The need for assay sensitivity in clinical trials must
be understood if we are to eliminate trials that are unethical because they have no
chance of showing a clear and scientifically valid answer.
Another advantage of placebo as a control is that generally, smaller groups of
patients are required to demonstrate proof of concept with the new drug than would be
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necessary with an active comparator, thus reducing the number of patients exposed to
the potential risk factors. Placebos may be inert and lacking in specific therapeutic
effect but this cannot be said of the patients or physicians, which partly explains the
wide variability, ranging from about 25 - 60%, and inconsistencies in placebo
response rates in different studies. Placebo is not devoid of therapeutic benefit, nor is
it synonymous with nothing. Even if it were, it is well to recall that penicillin became
widely used because it was so obviously more effective than the best available
treatment for infections in the pre-antibiotic era, namely nothing. In other words,
one could say that penicillin was used only because it was 'better than nothing.' In his
derisive dismissal 'who cares if the new drug is better than nothing?' had Bradford Hill
forgotten penicillin and why was Rothman so eager to quote him?
Burt/TITP 166
XV. CONCLUSION - ESSENTIAL!
I began this thesis with a quotation from Humpty Dumpty concerning which
particular definition of a word was to be the master. Placebo has been called many
things, as we have seen. It has been a prayer, a ceremony, a sycophant, a
treatment given only to please the patient, an unacceptable deception, a lie, a
valuable item of the therapeutic armamentarium, an important therapeutic device and
a respected tool in modern research. It has been described as quackery and in terms
of derision, embarrassment and disdain, as having a not inconsiderable place in
medicine, not to be discussed in polite society and unfit for publication. Quite a
vocabulary from which to choose the word that is to be master.
In a recent article (344) the authors described their systematic review of 130
trials in which treatment with placebo was compared with no treatment, and
attempted to understand the effects of placebo as a treatment rather than the effects
of placebo as a comparator in clinical trials. They suggested that there is no
justification for the use of placebo as a treatment, outside the clinical trial setting, and
they are supported by the author of an accompanying Editorial who agreed that he
would wish neither to prescribe nor receive a placebo, as treatment (345). Both note
that within a double blind, randomised clinical trial setting however, the use of
placebo is a precaution against many forms of bias and not simply a way of controlling
for the placebo effects.
It must be clear, therefore, that choice of the word that is to be master must
accept that there is no role in modern medicine for placebo as a therapy. We are
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concerned only with the use of placebo in medical research, specifically in clinical trials
of the double blind, randomised design.
'Where would the evidentiary basis of medicine be without the
randomized, double-blind, placebo-controlled trial?' asked Desbiens (342) as
he discussed the daunting problems of making matching supplies of marketed drugs for
clinical comparison.
'Placebos still constitute an important methodological tool in
establishing the internal validity of a trial.' stated some clinical investigators
from London and Amsterdam (343) as they considered a specific study design.
'The reference treatment should consist of placebo and best
supportive care.' proposed the clinical pharmacological assessor to the Dutch
Medicines Evaluation Board (321) as he considered study designs for new treatments
for cancer, HIV infections and other life threatening diseases.
'I have concluded that the placebo has made probably the single most
important contribution to modern therapeutics of any drug.' wrote a clinical
pharmacologist who is also the chairman of an academic department at Tulane
University (346).
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For a final word to the critics of placebo use in clinical trials I selected a quote
from Lasagna (199), who trained under Beecher and with whom he published a
number of seminal articles on analgesic research. Lasagna's contributions to all
aspects of drug development are well known and respected world wide. On the
subject of placebo he addresses Rothman and his supporters by recalling the words
that Oliver Cromwell wrote in a letter to the Church of Scotland: "I beseech you, in
the bowels of Christ, think it possible you may be mistaken."
My sentiments, entirely.
Oh yes, I have found the master word that defines the role of placebo in drug
development and scientifically rigorous clinical research. It is ESSENTIAL.
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